Open Acces

#### ORIGINAL ARTICLE

# Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients

Peng Song<sup>1</sup>, Dingding Zhang<sup>2</sup>, Xiaoxia Cui<sup>1</sup>, & Li Zhang<sup>1</sup>

1 Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China

2 Central Research Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China

#### Keywords

Cancer; immune checkpoint inhibitor (ICI); immune-related adverse events (irAEs).

Correspondence

Li Zhang, Department of Respiratory Medicine, Peking Union Medical College Hospital, Xinkai Road, DongCheng, Beijing, China. Tel: +86 10 6915 8760 Fax: +86 10 6915 5039 Email: zhanglipumch@aliyun.com

<sup>†</sup>Peng Song, Dingding Zhang and Xiaoxia Cui contributed equally

Received: 27 January 2020; Accepted: 30 May 2020.

doi: 10.1111/1759-7714.13541

Thoracic Cancer 11 (2020) 2406-2430

#### Abstract

**Background:** Immune checkpoint inhibitors (ICIs) have significant clinical efficacy in the treatment of non-small cell lung cancer (NSCLC); however, the incidence of immune-related adverse events (irAEs) of up to 50% has prevented their widespread use. With the increase in the use of ICIs alone or as combination therapy, clinicians are required to have a better understanding of irAEs and be able to manage them systematically. In this study, we aimed to assess the incidence of irAEs associated with ICIs.

**Methods:** We searched PubMed, Embase, and the Web of Science databases, and also included relevant literature references to widen our search. The relevant data with inclusion criteria were performed using RevMan 3.6.0 for meta-analysis. We undertook a systematic literature search which included published data up to December 2019.

Results: Overall, 147 articles and 23 761 cancer patients with 11 different ICI treatment-related (grade 1-5 and 3-5) irAEs were included in the study. There were 46 articles on pembrolizumab (6598 patients), 27 on nivolumab (3576 patients), 13 on atezolizumab (2787 patients), 12 on avelumab (3213 patients), 10 on durvalumab (1780 patients), 22 on ipilimumab (4067 patients), eight on tremelimumab (1158 patients), three on JS001 (223 patients), four on camrelizumab (SHR-1210) (178 patients), one on sintilimab (96 patients), and one on cemiplimab (85 patients). Grade 1-5 irAEs were: cytotoxic T lymphocyte antigen 4 (CTLA-4) (82.87%), programmed cell death 1 (PD-1) (71.89%), and programmed cell death ligand-1 (PD-L1) (58.95%). Subgroup analysis was: Avelumab (44.53%), durvalumab (66.63%), pembrolizumab (67.25%), atezolizumab (68.77%), nivolumab (76.25%), Ipilimumab (82.18%), and tremelimumab (86.78%). Grade 3-5 irAEs were: CTLA-4 (27.22%), PD-1 (17.29%), and PD-L1(17.29%). Subgroup analysis was: Avelumab (5.86%), durvalumab (13.43%),atezolizumab (14.45%),nivolumab (15.72%),pembrolizumab (16.58%), tremelimumab (22.04%), and ipilimumab (28.27%). Conclusions: This meta-analysis confirmed that anti-PD-1 and anti-PD-L1 inhibitors had a lower incidence of irAEs compared with anti-CTLA-4 inhibitors.

### Introduction

Immune checkpoint inhibitors (ICIs) act on cell surface checkpoint proteins to detect and destroy cancer cells through the autoimmune system, and can effectively be used to treat many types of malignant tumors. However, such treatment could lead to immune-related adverse events (irAEs).<sup>1</sup> ICIs include monoclonal antibodies (mAbs) against programmed cell death receptor-1 (PD-1),

**2406** Thoracic Cancer **11** (2020) 2406–2430 © 2020 The Authors. *Thoracic Cancer* published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PD-1 ligand (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), which have been approved for the treatment of advanced malignant tumors. PD-1 and CTLA-4 belong to the CD28 superfamily. PD-1 transmits a negative signal to T cells after binding to one of its two ligands (PD-L1 or PD-L2).<sup>2</sup> When PD-1 binds to its ligand, it inhibits the kinase involved in T cell activation, which allows tumor cells to escape immune detection and attack.<sup>3</sup> ICIs have been approved by the US Food and Drug Administration (FDA) for the treatment of advanced malignancies such as melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), urothelial carcinoma, head and neck squamous cell carcinoma, and Hodgkin's lymphoma. Because ICIs can activate T cells, its adverse reactions are different from traditional cytotoxic chemotherapy and are immune-mediated responses such as colitis, hepatitis, thyroiditis, pituitary inflammation, pneumonia, pericarditis, hypothyroidism, nephritis, fatigue, and rash.4

ICIs are constantly experiencing exploration from second-line to first-line therapies. After 2011, following numerous clinical trials and studies, the FDA successively approved pembrolizumab, nivolumab (PD-1), atezolizumab, avelumab, durvalumab (PD-L1), followed by the approval of ipilimumab, and currently tremelimumab (CTLA-4) is undergoing a large number of clinical trials. From 2017 to 2018, China's immunization research progressed rapidly, and PD-1 ICIs (JS001, SHR-1210, and sintilimab) became available in China. Cemiplimab has been approved by the FDA and has become the world's third type of PD-1 ICI. These immune drugs have shown good responses to malignant tumors, but their accompanying irAEs should not be ignored.

With the deepening of clinical research to clinical practice, tumor immunotherapy has accumulated more and more research data in the treatment of indications, the selection of biomarkers, and the prevention and treatment of AEs related to immunotherapy. Here, we conducted a comprehensive meta-analysis of single drug immunotherapy for different cancer types and different ICI treatmentrelated AEs to provide an effective data support for future clinical immunotherapy decisions.

#### Methods

## Literature search and eligibility criteria

A systematic literature search for relevant articles was conducted which included single- or two-arm clinical trials of immunotherapy with a single drug for malignant tumors. Inclusion criteria were as follows: the study subjects were patients with malignant tumors receiving ICI monotherapy, regardless of age, gender, nationality, and ethnicity. Interventions: the experimental group consisted of patients who had received ICI monotherapy and the control group of patients who had received conventional chemotherapy. Outcome indicators were evaluable ICI-related AEs. Document exclusion criteria were: (i) unable to obtain full-text, or repeated publication studies; (ii) documents with incomplete data or lack of original extractable data; and (iii) summary or no indicators for evaluation.

#### Search strategy

The database searches included PubMed, Web of Science, and Embase. The single- or two-arm clinical trials were published in English from January 2007 to May 2019. The combination of key words and free words to search included specific ICI drug names: Pembrolizumab, avelumab, nivolumab, atezolizumab, durvalumab, ipilimumab, tremelimumab, JS001, SHR-1210, sintilimab, and cemiplimab, and keywords were immunological checkpoints (PD-1, PD-L1, CTLA-4) to search for relevant English studies of immunotherapy. A supplementary literature search was also undertaken which included the references in the literature.

#### **Document screening method**

Two researchers independently (XY Cui, P Song) conducted a literature search and screening according to the Quality of Reporting of Meta-Analyses (QUORUM). The literature screening was based on the predetermined inclusion or exclusion criteria. First, the researchers read the title and abstract, later, read the full text to screen the qualified documents. In case of disagreement, the research team collectively discussed the solution.

#### **Data extraction**

Data were extracted according to the same data extraction table. The final results were crosschecked. The extracted data included mainly treatment-related and immune-mediated research data and the following data were extracted: PMID, first author, study year, cancer type, region, the total number of trials, enrollment included in safety analysis, study phase, treatment plan, common AE assessment version, the total number of grade 1–5 ICI-related AEs and grade 3–5 ICI-related AEs, specific data and frequency of various AE reports.

#### **Statistical analysis**

#### **Combined effect values**

The incidence of AEs in the original study was calculated by recording the sample size of the original study and the number of AEs. The inverse variance method was used to combine the incidence of AEs in a single study to draw the forest map. A fixed-effect or a random effect model was selected based on the heterogeneity test result. When the heterogeneity between studies was larger and the heterogeneity source could not be found by stratified analysis, the combined results of individual study AEs should be carefully interpreted.

#### Heterogeneity test

The interstudy heterogeneity (I<sup>2</sup>) was calculated using the DerSimonian-Laird estimate method; the heterogeneity between studies was analyzed by chi-square test. When P > 0.10, I<sup>2</sup>  $\leq$  50%, there was no heterogeneity between them; when  $P \leq 0.10$ , I<sup>2</sup> > 50%, there was a larger heterogeneity between the studies.

#### **Publication bias test**

By drawing a funnel chart and observing its symmetry, the risk of publication bias was initially determined. If the funnel chart showed symmetry, it indicated that there was no publication bias; if the funnel chart showed asymmetry, it indicated that there was a publication bias. At the same time, the symmetry of the funnel chart was judged by a rank correlation test.

#### **Hierarchical analysis**

We performed a stratified analysis according to specific ICI drug varieties. Statistical analysis was conducted with the meta-analysis package of R software (3.6.0), using the metaprop, forest, funnel, and metabias commands.

#### Results

#### Literature screening

The literature was first screened by reading the title and abstract and then some articles were removed if they were meeting abstracts, there was no inconsistent design, no access to the full text, and incomplete data. At the commencement of the study, a total of 220 related articles were identified, including 198 in PubMed, 12 in Embase and 10 in the web of Science, excluding 42 abstract papers, six quality of life analysis articles, 11 retrospective articles, 14 articles on immunocombination, and finally 147 cases of immunotherapy with a single drug to provide specific AE data of 23 761 patients (Fig 1).

#### **Basic characteristics of the literature**

This analysis compared 11 different ICI-related (grade 1–5 and 3–5) AEs, including a total of 147 studies and 23 761 patients.<sup>5–149</sup> The interventions were: 46 pembrolizumab



Figure 1 Flowchart of study selection and design.

articles (n = 6598),<sup>5–49</sup> 27 nivolumab articles (n = 3576),<sup>49–75</sup> 13 atezolizumab articles (n = 2787),<sup>76–88</sup> 12 avelumab articles (n = 3213),<sup>89–102</sup> 10 durvalumab articles (n = 1780),<sup>103–111</sup> 22 ipilimumab articles  $(n = 4067)^{5, 112-132}$ ; eight tremelimumab articles (n = 1158),<sup>133–140</sup> three JS001 articles (n = 223),<sup>141–143</sup> four SHR-1210 articles (n = 178),<sup>144–147</sup> one sintilimab articles  $(n = 96)^{148}$  and one cemiplimab article (n = 85).<sup>149</sup>

#### **Meta-analysis results**

### Meta-analysis based on grade 1–5 adverse events of different ICIs in malignant tumors

The inverse variance method was used to analyze the incidence of grade 1–5 AEs of conventional therapy and three different immunological drugs CTLA-4, PD-1, and PD-L1 to draw a forest plot. A total of 18 articles reported grade 1–5 AEs to conventional therapy. Heterogeneity analysis showed statistical heterogeneity among the results of each study (P < 0.1,  $I^2 = 81.9\%$ ), so a random effects model was used. The results of meta-analysis showed that the incidence of AEs was 83.81% (95% CI: 0.8113–0.8617, P < 0.1,  $I^2 = 81.9\%$ ), and the forest plot is shown in Fig 2. A total of 32 articles reported CTLA –4 grade 1–5 AEs, heterogeneity analysis showed statistical heterogeneity between the results of each study (P < 0.1,  $I^2 = 94.1\%$ ), so the random-

а	Study	Events	Total		Proportion	95%-Cl	Weight (fixed)	Weight (random)
a	Study Ribas et al[9] Reck et al[16] Herbst et al[10] Plimack et al[18] Shitara et al[31] Cohen et al[33] Mok et al[37] Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Rittmeyer et al[79] Fehrenbacher et al[87] Powles et al[81] Barlesi et al[97] Barag et al[12]	Events 138 135 251 230 232 196 553 81 236 111 243 86 496 119 395 313 121	171           151           309           272           276           248           615           102           290           137           270           121           578           143           365           126		Proportion 0.81 0.89 0.81 0.85 0.84 0.79 0.90 0.79 0.81 0.81 0.90 0.71 0.86 0.83 0.83 0.89 0.86	95%-Cl [0.74; 0.86] [0.83; 0.94] [0.76; 0.85] [0.79; 0.88] [0.73; 0.84] [0.77; 0.92] [0.76; 0.87] [0.76; 0.86] [0.73; 0.87] [0.86; 0.93] [0.62; 0.79] [0.83; 0.89] [0.76; 0.89] [0.86; 0.92] [0.82; 0.89] [0.82; 0.89]	(fixed) 4.2% 2.2% 7.4% 5.6% 5.8% 6.5% 8.8% 2.6% 6.9% 3.3% 3.8% 3.9% 11.1% 3.1% 6.7% 7.0%	(random) 5.4% 4.5% 6.0% 5.7% 5.7% 5.8% 6.1% 4.7% 5.9% 5.3% 6.3% 5.3% 6.3% 5.3% 6.3% 5.0% 5.9% 5.9%
	Ribas et al[137]	292	327		0.89	[0.85; 0.92]	4.9%	5.6%
	Fixed effect model Random effects model Heterogeneity: $I^2 = 82\%$ , $\tau$	<sup>2</sup> = 0.1291	<b>5004</b> , <i>p</i> < 0.		0.84 0.84	[0.83; 0.85] [0.81; 0.86]	100.0%	 100.0%
			-	0.65 0.7 0.75 0.8 0.85 0.9				
b	Study	Events	Total		Proportion	95%-CI	Weight (fixed)	Weight (random)
	Weber et al[114]	434	453	÷	0.96	[0.94: 0.97]	2.5%	3.6%
	Larkin et al[72]	268	311		0.86	[0.82; 0.90]	5.1%	3.7%
	Robert et al[5]	187	256		0.73	[0.67; 0.78]	7.0%	3.7%
	Ribas et al[137]	312	328	-#	0.95	[0.92; 0.97]	2.1%	3.5%
	Weber et al[114]	63	88		0.72	[0.61; 0.81]	2.5%	3.6%
	Jeffrey et al[131]	48	57		0.84	[0.72; 0.93]	1.0%	3.3%
	Oday et al[132]	109	115		0.95	[0.89; 0.98]	0.8%	3.1%
	Wolchok et al[133]	115	214		0.54	[0.47; 0.61]	7.3%	3.7%
	Omid et al[126]	50	82		0.61	[0.50; 0.72]	2.7%	3.6%
	Slovin et al[113]	8	8		1.00	[0.63; 1.00]	0.1%	1.0%
	Slovin et al[113]	16	16		0.83	[0.36; 1.00]	0.1%	1.5%
	Slovin et al[113] Vamazaki ot al[115]	10	60		0.20	[0.79; 1.00]	1.2%	1.0% 3.4%
	Fagermont et al[116]	/26	/71	-	0.20	[0.11, 0.32]	5.6%	3.4%
	Ascierto et al[117]	228	362		0.50	[0.58: 0.68]	11 7%	3.8%
	Ascierto et al[117]	286	364		0.79	[0.74: 0.83]	8.5%	3.8%
	Beer et al[118]	325	399		0.81	[0.77; 0.85]	8.3%	3.8%
	Chesney et al[119]	90	95		0.95	[0.88; 0.98]	0.7%	3.0%
	Weber et al[120]	434	453	+	0.96	[0.94; 0.97]	2.5%	3.6%
	Bang et al[121]	41	57		0.72	[0.58; 0.83]	1.6%	3.4%
	Zimmer et al[122]	71	103		0.69	[0.59; 0.78]	3.0%	3.6%
	Weber et al[123]	18	20		0.90	[0.68; 0.99]	0.2%	2.2%
	Geoerger et al[124]	12	12		1.00	[0.74; 1.00]	0.1%	1.0%
	Hersh et al[125]	24	39		0.62	[0.45; 0.77]	1.3%	3.3%
	Chesney et al[119]	90	95		0.95	[0.88; 0.98]	0.7%	3.0%
	Postow et al[127]	43	46		0.93	[0.82; 0.99]	0.4%	2.6%
	Larkin et al[128]	208	311		0.80	[0.82; 0.90]	5.1%	3.7%
	Robert et al[130]	100	256		0.00	[0.72, 0.07]	2.9% 7 0%	3.0%
	Chung et al[136]	30	47		0.73	[0.49: 0.77]	1.5%	3.4%
	Calabrò et al[138]	26	29		0.90	[0.73: 0.98]	0.4%	2.5%
	Maio et al[140]	329	380		0.87	[0.83; 0.90]	6.1%	3.7%
	Fixed effect model		5664	•	0.79	[0 78. 0 80]	100.0%	
	Random effects model		5004	*	0.83	[0.78: 0.87]		100.0%
	Heterogeneity: $I^2 = 94\%$ , $\tau$	<sup>2</sup> = 0.7274	l, p < 0.		0.00	[21. 5, 5107]		
				0.2 0.4 0.6 0.8	I			

Figure 2 (a) Forest plot of conventional therapy; and (b) CTLA-4 for grade 1–5 adverse events (AEs).

effects model was used for consolidation. Meta-analysis showed that the incidence of AEs was 82.87% (95% CI: 0.7771–0.8704, P < 0.1,  $I^2 = 94.1\%$ ), and the forest plot is shown in Fig 3. There were 72 reports which reported PD-1 grade 1-5 AEs, and heterogeneity analysis showed that the statistical heterogeneity between the results of each study was greater (P < 0.1,  $I^2 = 92.4\%$ ), so the randomeffects model was used for the combination. Meta analysis results showed that the reaction rate was 71.89% (95% CI: 0.6811-0.7539, P < 0.1,  $I^2 = 92.4\%$ ), and its forest plot is shown in Fig 4. A total of 32 articles reported grade 1-5 AEs of PD-L1 heterogeneity analysis indicating that the statistical heterogeneity between the results was greater  $(P < 0.1, I^2 = 97.9\%)$ , so the random-effects model was used for the combination. The meta-analysis showed that the incidence of AEs was 58.95%. (95% CI: 0.4906-0.6817, P < 0.1,  $I^2 = 97.9\%$ ), and the forest plot is shown in Fig 5.

### Subgroup analysis of grade 1–5 adverse events based on different ICIs in malignant tumors

There were 11 reports in the literature of grade 1-5 AEs to atezolizumab, and heterogeneity analysis showed statistical heterogeneity between studies was greater (P < 0.1,  $I^2 = 57.7\%$ ), so the random effects model was used for the combination. The meta-analysis showed that the incidence of AEs was 68.77% (95% CI: 0.6545-0.7190, P < 0.1,  $I^2 = 57.7\%$ ), and the forest plot is shown in Fig 6. There were 14 reports of avelumab grade 1-5 AEs, and heterogeneity analysis showed greater statistical heterogeneity between the results of each study (P < 0.1,  $I^2 = 98.3\%$ ), so the random effects model was used for the combination. The meta-analysis showed that the incidence of AEs was 44.53% (95% CI: 0.2759–0.6285, P < 0.1,  $I^2 = 98.3\%$ ), and the forest plot is shown in Fig 7. A total of seven articles reported durumumab grade 1-5 AEs, and heterogeneity analysis showed statistical heterogeneity among the results of each study was greater (P < 0.1,  $I^2 = 95.9\%$ ), so the random effects model was used for the merger. Meta-analysis results showed that the incidence rate of AEs was 66.63% (95% CI: 0.4855–0.8086, P < 0.1,  $I^2 = 95.9\%$ ), and the forest plot is shown in Fig 8. There were 28 articles which reported ipilimumab grade 1-5 AEs, and heterogeneity analysis showed statistical heterogeneity among the results of each study (P < 0.1,  $I^2 = 94.1\%$ ), so the random effects model was used for the merger. Meta-analysis results showed the incidence of AEs was 82.18% (95% CI: 0.7649-0.8673, P < 0.1,  $I^2 = 94.1\%$ ), and the forest plot is shown in Fig 9. A total of 26 articles indicated grade 1-5 AEs to nivolumab, and heterogeneity analysis showed greater statistical heterogeneity between the results of each study  $(P < 0.1, I^2 = 90.7\%)$ , so the random effects model was used for the combination. Meta-analysis showed that the incidence of AEs was 76.25% (95% CI: 0.7035-0.8129, P < 0.1,  $I^2 = 90.7\%$ ), and its forest plot is shown in Fig 10. There were 41 articles which reported pembrolizumab grade 1–5 AEs, and heterogeneity analysis showed statistical heterogeneity among the results of each study (P < 0.1,  $I^2 = 91.4\%$ ), so the random effects model was used for the combination. Meta-analysis showed that its AE occurrence rate was 67.25% (95% CI: 0.6257–0.7161, P < 0.1,  $I^2 = 91.4\%$ ), and its forest plot is shown in Fig 11. Four articles reported grade 1–5 AEs from tremelimumab, and heterogeneity analysis showed that the statistical heterogeneity between the study results was high (P < 0.1,  $I^2 = 91.9\%$ ), so the random effects model was used for the combination. The meta-analysis showed that the incidence of AEs was 86.78% (95% CI: 0.7172–0.9445, P < 0.1,  $I^2 = 91.9\%$ ), and the forest plot is shown in Fig 12.

#### Risk assessment of publication bias based on grade 1– 5 adverse events in different ICIs in malignant tumors

All studies included in our analyses reported grade 1-5 AEs. To obtain a total overview, we performed a funnel plot. The points on the funnel plot were approximately symmetric, indicating that there was no publication bias. The P publication bias of the 18 studies included in conventional therapy was >0.05, and therefore no publication bias was found. The P publication bias of 32 studies included in CTLA-4 was >0.05, and therefore no publication bias was found. The P publication bias of 32 studies included in PD-L1 was >0.05, and therefore no publication bias was found. The P publications of 72 samples included in PD-1 had a bias of P < 0.05, indicating that there was a risk of bias. The funnel plot is shown in Fig 13. In total, 11 articles reported grade 1-5 AEs to atezolizumab, and P publication bias was > 0.05, indicating that no publication bias was found.

A total of 14 articles reported that the avelumab grade 1–5 AEs *P* published bias was >0.05, indicating that no publication bias was found. There were seven articles which reported that the grade 1–5 AEs to durvalumab were unclear. In 28 articles, the grade 1–5 AEs to ipilimumab was reported to have had a *P* bias >0.05, indicating no publication bias was found. In 26 papers it was reported that grade 1–5 AEs to nivolumab *P* publication bias was >0.05, and therefore no publication bias was found. A total of 41 articles reported that the pembrolizumab grade 1–5 AEs *P* publication bias was >0.05, and no published bias was found. Four articles reported that the bias of grade 1–5 AEs to tremelimumab was unclear.

#### Meta-analysis based on grade 3–5 adverse events of different ICIs in malignant tumors

The inverse-variance weighting method was used to analyze the incidence of grade 3–5 AEs of conventional therapy and three different immunological drugs - CTLA-4, PD-1, and PD-L1 - and a forest plot was drawn. There

**Figure 3** Forest plot of PD-1 for grade 1–5 adverse events (AEs).

Study	Events	Total		Proportion	95%-CI	Weight (fixed)	Weight (random)
Ribas et al[9]	252	357		0.71	[0.66; 0.75]	3.5%	1.9%
Reck et al[16]	113	154		0.73	[0.66; 0.80]	1.4%	1.9%
Herbst et al[10]	441	682		0.65	[0.61; 0.68]	7.4%	2.0%
Plimack et al[18]	162	266		0.61	[0.55; 0.67]	3.0%	1.9%
Cohen et al[33]	155	294 246		0.63	[0.47, 0.59]	2.7%	1.9%
Mok et al[37]	399	636	-	0.63	[0.59; 0.67]	7.0%	2.0%
Weber et al[70]	181	268		0.68	[0.62; 0.73]	2.8%	1.9%
Borghaei et al[67]	199	287		0.69	[0.64; 0.75]	2.9%	1.9%
Carbone et al[71]	190	267		0.56	[0.49, 0.67] [0.65; 0.77]	2.6%	1.9%
Ferris et al[74]	139	236		0.59	[0.52; 0.65]	2.7%	1.9%
Weber et al[114]	385	452	-	0.85	[0.82; 0.88]	2.7%	1.9%
Larkin et al[72]	257	316		0.81	[0.77; 0.85]	2.3%	1.9%
Robert et al[5]	221	556 405	*	0.40	[0.36; 0.44]	6.3%	2.0%
Patnaik et al[7]	21	30		0.70	[0.51; 0.85]	0.3%	1.5%
Le et al[21]	40	41		0.98	[0.87; 1.00]	0.0%	0.6%
Shimizu et al[11]	8	10		0.80	[0.44; 0.97]	0.1%	0.8%
Nghiem et al[12]	20	26		0.77	[0.56; 0.91]	0.2%	1.3%
Seiwert et al[13]	20 38	39 60		0.67	[0.50, 0.61]	0.4%	1.0%
Plimack et al[18]	20	33		0.61	[0.42; 0.77]	0.4%	1.5%
Hui et al[19]	86	101		0.85	[0.77; 0.91]	0.6%	1.7%
Naoya et al[3]	34	42		0.81	[0.66; 0.91]	0.3%	1.5%
Alley et al[43]	16	25		0.64	[0.43; 0.82]	0.3%	1.4%
Wei et al[4]	25	25		1 00	[0.36, 0.71]	0.0%	0.3%
Ott et al[17]	16	25		0.64	[0.43; 0.82]	0.3%	1.4%
Ott et al[17]	13	24		0.54	[0.33; 0.74]	0.3%	1.4%
Ott et al[17]	24	24		1.00	[0.86; 1.00]	0.0%	0.3%
Schachter et al[22]	442 220	555 370		0.80	[0.76; 0.83]	4.3%	1.9%
Frenel et al[46]	18	24		0.75	[0.53; 0.90]	0.2%	1.3%
Doi et al[47]	9	23		0.39	[0.20; 0.61]	0.3%	1.4%
Cohen et al[26]	22	26	_	0.85	[0.65; 0.96]	0.2%	1.2%
Fuchs et al[27]	156	259		0.60	[0.54; 0.66]	2.9%	1.9%
Eggermont et al[29]	190	514	+	0.04	[0.43, 0.62]	0.3 % 5.7%	2.0%
Zhu et al[30]	76	104		0.73	[0.63; 0.81]	1.0%	1.8%
Hansen et al[32]	14	23		0.61	[0.39; 0.80]	0.3%	1.4%
Adams et al[48]	53	84		0.63	[0.52; 0.73]	0.9%	1.8%
Shah et al[34]	70	121		0.73	[0.52; 0.88]	0.2%	1.4%
Levy et al[36]	49	49		1.00	[0.93; 1.00]	0.0%	0.3%
Yamamoto et al[54]	3	3		1.00	[0.29; 1.00]	0.0%	0.3%
Yamamoto et al[54]	5	5		1.00	[0.48; 1.00]	0.0%	0.3%
Yamamoto et al[54]	63	6		1.00	[0.54; 1.00]	0.0%	0.3%
D'Angelo et al[65]	84	84	_	1.00	[0.96; 1.00]	0.0%	0.3%
Kang et al[73]	141	330		0.43	[0.37; 0.48]	3.8%	1.9%
Motzer et al[69]	319	410		0.78	[0.73; 0.82]	3.3%	1.9%
Larkin et al[72]	257	313		0.82	[0.77; 0.86]	2.2%	1.9%
Hamanishi et al[63]	9	25 10		0.64	[0.43, 0.62]	0.3%	0.6%
Hamanishi et al[63]	10	10		1.00	[0.69; 1.00]	0.0%	0.3%
Kudo et al[62]	47	65		0.72	[0.60; 0.83]	0.6%	1.7%
Maruyama et al[56]	17	17		1.00	[0.80; 1.00]	0.0%	0.3%
NISNIO Et al[60]	64 51	76 74		0.84	[0.74; 0.92]	0.5%	1.6%
Rizvi et al[64]	87	117		0.74	[0.65: 0.82]	1.1%	1.8%
Yamazaki et al[59]	20	24		0.83	[0.63; 0.95]	0.2%	1.2%
Younes et al[55]	71	80		0.89	[0.80; 0.95]	0.4%	1.5%
Ansell et al[66]	18	23		0.78	[0.56; 0.93]	0.2%	1.2%
Midden et al[149]	59	59	_	1.00	[0.94: 1.00]	0.0%	0.3%
Tang et al[142]	36	36	—	1.00	[0.90; 1.00]	0.0%	0.3%
Nie et al[145]	19	86		0.22	[0.14; 0.32]	0.7%	1.7%
Bang et al[38]	24	56		0.43	[0.30; 0.57]	0.6%	1.7%
Chung et al[40]	98	98		· 1.00	[0.96; 1.00]	0.0%	0.3%
Shi et al[148]	89	96		0.93	[0.86; 0.97]	0.3%	1.5%
Fixed effect model		10827	۰ ۲	0.65	[0.64; 0.65]	100.0%	100.0%
Heterogeneity: $I^2 = 92\%$	$r^2 = 0.4237$	. p < 0.0	1	0.72	[0.00, 0.75]		100.0%
		. ,	0.2 0.4 0.6 0.8	1			

Study	Events	Total		Proportion	95%-CI	Weight (fixed)	Weight (random)
Rittmever et al[79]	390	609		0.64	[0 60 <sup>.</sup> 0 68]	11.0%	3.3%
Fehrenbacher et al[87]	95	142		0.67	[0.59: 0.75]	2.5%	3.2%
Powles et al[81]	319	459		0.69	[0.65: 0.74]	7.6%	3.3%
Barlesi et al[97]	251	393		0.64	[0.59; 0.69]	7.1%	3.3%
Bang et al[121]	90	184		0.49	[0.41; 0.56]	3.6%	3.3%
Peters et al[80]	429	659	-	0.65	[0.61; 0.69]	11.8%	3.3%
Petrylak et al[82]	64	95		0.67	[0.57; 0.77]	1.6%	3.2%
Colevas et al[86]	21	32		0.66	[0.47; 0.81]	0.6%	3.0%
Horn et al[85]	68	89		0.76	[0.66; 0.85]	1.3%	3.2%
Lukas et al[84]	10	16		0.62	[0.35; 0.85]	0.3%	2.7%
Spigel et al[83]	96	137		0.70	[0.62; 0.78]	2.3%	3.2%
McDermott et al[77]	59	65		0.91	[0.81; 0.97]	0.4%	2.9%
Gulley et al[90]	22	184		0.12	[0.08; 0.18]	1.5%	3.2%
Dirix et al[93]	115	168		0.68	[0.61; 0.75]	2.8%	3.2%
Chung et al[102]	85	150		0.57	[0.48; 0.65]	2.9%	3.2%
Disis et al[101]	21	125		0.17	[0.11; 0.25]	1.4%	3.2%
Apolo et al[92]	29	44		0.66	[0.50; 0.80]	0.8%	3.1%
Patel et al[94]	244	249		+ 0.98	[0.95; 0.99]	0.4%	2.9%
Kelly et al[95]	247	1738	+	0.14	[0.13; 0.16]	16.6%	3.3%
Keilholz et al[100]	5	51	-+	0.10	[0.03; 0.21]	0.4%	2.8%
Hassan et al[99]	12	53		0.23	[0.12; 0.36]	0.7%	3.1%
Heery et al[91]	5	53		0.09	[0.03; 0.21]	0.4%	2.8%
Le et al[98]	20	25		0.80	[0.59; 0.93]	0.3%	2.8%
Antonia et al[104]	460	473	-	+ 0.97	[0.95; 0.99]	1.0%	3.1%
Yang et al[107]	23	68		0.34	[0.23; 0.46]	1.2%	3.2%
Massard et al[103]	39	61		0.64	[0.51; 0.76]	1.1%	3.1%
Segal et al[111]	37	62		0.60	[0.46; 0.72]	1.2%	3.1%
Zandberg et al[110]	64	112		0.57	[0.47; 0.66]	2.2%	3.2%
Siu et al[109]	41	67		0.61	[0.49; 0.73]	1.2%	3.2%
Herbst et al[/6]	194	2//	1	0.70	[0.64; 0.75]	4.6%	3.3%
Garassino et al[105]	256	444		0.58	[0.53; 0.62]	8.5%	3.3%
Apolo et al[92]	29	44		0.66	[0.50; 0.80]	0.8%	3.1%
Fixed effect model		7328	\$	0.53	[0.52; 0.54]	100.0%	
Random effects model				0.59	[0.49; 0.68]		100.0%
Heterogeneity: $I^2 = 98\%$ , $\tau$	r <sup>∠</sup> = 1.2536	8, <i>p</i> < 0					

Figure 4 Forest plot of PD-L1 for grade 1–5 adverse events (AEs).

were 18 grade 3-5 AEs to conventional therapy. Heterogeneity analysis showed statistical heterogeneity among the results of each study (P < 0.1,  $I^2 = 88.7\%$ ), so the random effects model was used. The results of meta-analysis showed that the incidence of AEs was 41.28% (95% CI: 0.3714-0.4555, P < 0.1, I2 = 88.7%), and its forest plot is shown in Figure 14. A total of 36 reports revealed CTLA-4 grade 3-5 AEs, and heterogeneity analysis showed greater statistical heterogeneity between the results of each study (P < 0.1, I2 = 92.6%), so the random effects model was used for consolidation. Meta-analysis showed that the incidence of AEs was 27.22% (95% CI: 0.2287-0.3204, P < 0.1, I2 = 92.6%), and its forest plot is shown in Fig 15. A total of 76 articles reported PD-1 grade 3-5 AEs, and heterogeneity analysis showed that the statistical heterogeneity between the results of each study was greater (P < 0.01, I2 = 86.7%), so the random effects model was used for the combination. The meta-analysis results showed that the incidence of AEs was 17.29% (95% CI: 0.1504–0.1979, P < 0.1,  $I^2 = 86.7\%$ ). There were 28 articles which reported PD-L1 grade 3–5 AEs, and heterogeneity analysis showed that the statistical heterogeneity between the results of each study was greater (P < 0.1,  $I^2 = 92.1\%$ ), so the random effects model was used for the combination. The meta-analysis showed that the incidence of AEs was 17.29% (95% CI: 0.0808–0.1397, P < 0.1,  $I^2 = 92.1\%$ ).

### Subgroup analysis of grade 3–5 adverse events based on different ICIs in malignant tumors

There were 11 articles which reported grade 3–5 AEs to atezolizumab. Heterogeneity analysis showed greater statistical heterogeneity among the results of each study (P < 0.1,  $I^2 = 50.2\%$ ), so the random effects model was used for merging. The meta-analysis showed that the

						Weight	Weight
а	Study	Events	Total	Proportion	95%-CI	(fixed)	(random)
	Rittmeyer et al[79]	390	609	0.64	[0.60; 0.68]	25.1%	15.9%
	Fehrenbacher et al[87]	95	142	0.67	[0.59; 0.75]	5.6%	9.5%
	Powles et al[81]	319	459	0.69	[0.65; 0.74]	17.4%	14.7%
	Peters et al[80]	429	659	0.65	[0.61; 0.69]	26.8%	16.1%
	Petrylak et al[82]	64	95	0.67	[0.57; 0.77]	3.7%	7.6%
	Colevas et al[86]	21	32		[0.47; 0.81]	1.3%	3.5%
	Horn et al[85]	68	89	.76	[0.66; 0.85]	2.9%	6.4%
	Lukas et al[84]	10	16	0.62	[0.35; 0.85]	0.7%	2.0%
	Spigel et al[83]	96	137	0.70	[0.62; 0.78]	5.1%	9.1%
	McDermott et al[77]	59	65	0.91	[0.81; 0.97]	1.0%	2.8%
	Herbst et al[76]	194	277	0.70	[0.64; 0.75]	10.4%	12.5%
	Fixed effect model		2580	<b>0.67</b>	[0.65; 0.69]	100.0%	
	Random effects model			<ul> <li>0.69</li> </ul>	[0.65; 0.72]		100.0%
	Heterogeneity: $I^2 = 58\%$ , $\tau$	<sup>2</sup> = 0.0299	9, p < 0	11			
				0.4 0.5 0.6 0.7 0.8 0.9			

b	Study	Events	Total					Proportion	95%-CI	Weight (fixed)	Weight (random)
	Barlesi et al[97]	251	393			-+-		0.64	[0.59; 0.69]	17.9%	7.5%
	Bang et al[121]	90	184			-		0.49	[0.41; 0.56]	9.1%	7.4%
	Gulley et al[90]	22	184					0.12	[0.08; 0.18]	3.8%	7.3%
	Dirix et al[93]	115	168					0.68	[0.61; 0.75]	7.2%	7.4%
	Chung et al[102]	85	150					0.57	[0.48; 0.65]	7.3%	7.4%
	Disis et al[101]	21	125					0.17	[0.11; 0.25]	3.5%	7.3%
	Apolo et al[92]	29	44		1			0.66	[0.50; 0.80]	2.0%	7.1%
	Patel et al[94]	244	249					+ 0.98	[0.95; 0.99]	1.0%	6.8%
	Kelly et al[95]	247	1738	+-	1			0.14	[0.13; 0.16]	41.9%	7.5%
	Keilholz et al[100]	5	51	<del></del>				0.10	[0.03; 0.21]	0.9%	6.7%
	Hassan et al[99]	12	53	+-	÷			0.23	[0.12; 0.36]	1.8%	7.1%
	Heery et al[91]	5	53	<del></del>	1			0.09	[0.03; 0.21]	0.9%	6.7%
	Le et al[98]	20	25				+	- 0.80	[0.59; 0.93]	0.8%	6.6%
	Apolo et al[92]	29	44			+		0.66	[0.50; 0.80]	2.0%	7.1%
	Fixed effect model		3461		\$			0.33	[0.31; 0.35]	100.0%	
	Random effects model	l		-	$\leq$			0.45	[0.28; 0.63]		100.0%
	Heterogeneity: $I^2 = 98\%$ , a	<sup>2</sup> = 1.9276	b, p < 0	.01							
				0.2	0.4	0.6	0.8				

С	Study	Events	Total		Proportion	95%-CI	(fixed)	(random)
	Antonia et al[104]	460	473	-	0.97	[0.95; 0.99]	6.1%	14.0%
	Yang et al[107]	23	68		0.34	[0.23; 0.46]	7.3%	14.1%
	Massard et al[103]	39	61		0.64	[0.51; 0.76]	6.7%	14.1%
	Segal et al[111]	37	62		0.60	[0.46; 0.72]	7.2%	14.1%
	Zandberg et al[110]	64	112		0.57	[0.47; 0.66]	13.1%	14.6%
	Siu et al[109]	41	67		0.61	[0.49; 0.73]	7.6%	14.2%
	Garassino et al[105]	256	444		0.58	[0.53; 0.62]	52.0%	15.0%
	Fixed effect model		1287	🔷	0.61	[0.58; 0.65]	100.0%	
	Random effects mode Heterogeneity: $l^2 = 96\%$	$\tau^2 = 0.968$	4 n < 0	01	0.67	[0.49; 0.81]		100.0%
	1 lotor ogonolty. 7 00 /0,	. 0.000	ι, μ · Ο	03040506070809				

Figure 5 (a) Forest plot of atezolizumab; (b) avelumab; and (c) durvalumab or grade 1–5 adverse events (AEs).

incidence of AEs was 14.45% (95% CI: 0.1236–0.1684, P < 0.1,  $I^2 = 50.2\%$ ). There were 10 articles which reported avelumab grade 3–5 AEs, and heterogeneity analysis

showed greater statistical heterogeneity between the results of each study (P < 0.1,  $I^2 = 88.9\%$ ), so the random effects model was used for consolidation. Meta-analysis showed

Woight Woight



0.3 0.4 0.5 0.6 0.7 0.8 0.9 1

Figure 6 (a) Forest plot of ipilimumab; and (b) nivolumab for grade 1–5 adverse events (AEs).

						Weight	Weight
Study	Events	Total		Proportion	95%-CI	(fixed)	(random)
Ribas et al[9]	252	357		0.71	[0.66; 0.75]	5.2%	3.3%
Reck et al[16]	113	154		0.73	[0.66; 0.80]	2.1%	3.2%
Herbst et al[10]	441	682	÷ + -	0.65	[0.61; 0.68]	10.9%	3.4%
Plimack et al[18]	162	266		0.61	[0.55; 0.67]	4.4%	3.3%
Shitara et al[31]	155	294		0.53	[0.47; 0.59]	5.1%	3.3%
Cohen et al[33]	155	246		0.63	[0.57; 0.69]	4.0%	3.3%
Mok et al[37]	399	636		0.63	[0.59; 0.67]	10.4%	3.4%
Robert et al[5]	221	556	-	0.40	[0.36; 0.44]	9.3%	3.4%
Garon et al[6]	351	495		0.71	[0.67; 0.75]	7.1%	3.4%
Patnaik et al[7]	21	30		0.70	[0.51; 0.85]	0.4%	2.3%
Le et al[21]	40	41		- 0.98	[0.87; 1.00]	0.1%	0.8%
Shimizu et al[11]	8	10		0.80	[0.44; 0.97]	0.1%	1.2%
Nghiem et al[12]	20	26		0.77	[0.56; 0.91]	0.3%	2.1%
Muro et al[13]	26	39		0.67	[0.50; 0.81]	0.6%	2.6%
Seiwert et al[14]	38	60		0.63	[0.50; 0.75]	1.0%	2.8%
Plimack et al[18]	20	33		0.61	[0.42; 0.77]	0.5%	2.5%
Hui et al[19]	86	101		0.85	[0.77; 0.91]	0.9%	2.8%
Naoya et al[3]	34	42		0.81	[0.66; 0.91]	0.5%	2.3%
Alley et al[43]	16	25		0.64	[0.43; 0.82]	0.4%	2.3%
Bauml et al[44]	109	171		0.64	[0.56; 0.71]	2.8%	3.2%
Wei et al[4]	25	25		⊣ 1.00	[0.86; 1.00]	0.0%	0.5%
Ott et al[17]	16	25		0.64	[0.43; 0.82]	0.4%	2.3%
Ott et al[17]	13	24		0.54	[0.33; 0.74]	0.4%	2.3%
Ott et al[17]	24	24		⊣ 1.00	[0.86; 1.00]	0.0%	0.5%
Schachter et al[22]	442	555		0.80	[0.76; 0.83]	6.3%	3.4%
Balar et al[23]	229	370		0.62	[0.57; 0.67]	6.1%	3.4%
Frenel et al[46]	18	24		0.75	[0.53; 0.90]	0.3%	2.0%
Doi et al[47]	9	23	*	0.39	[0.20; 0.61]	0.4%	2.2%
Cohen et al[26]	22	26		0.85	[0.65; 0.96]	0.2%	1.8%
Fuchs et al[27]	156	259		0.60	[0.54; 0.66]	4.3%	3.3%
Rugo et al[28]	16	25		0.64	[0.43; 0.82]	0.4%	2.3%
Eggermont et al[29]	190	514		0.37	[0.33; 0.41]	8.4%	3.4%
Zhu et al[30]	76	104		0.73	[0.63; 0.81]	1.4%	3.0%
Hansen et al[32]	14	23		0.61	[0.39; 0.80]	0.4%	2.2%
Adams et al[48]	53	84		0.63	[0.52; 0.73]	1.4%	3.0%
Varga et al[34]	19	26	*	0.73	[0.52; 0.88]	0.4%	2.2%
Shah et al[35]	70	121		0.58	[0.49; 0.67]	2.1%	3.2%
Levy et al[36]	49	49	— — — — — — — — — — — — — — — — — — —	→ 1.00	[0.93; 1.00]	0.0%	0.5%
Bang et al[38]	24	56		0.43	[0.30; 0.57]	1.0%	2.8%
Si et al[39]	103	103		- 1.00	[0.96; 1.00]	0.0%	0.5%
Chung et al[40]	98	98	-	⊣ 1.00	[0.96; 1.00]	0.0%	0.5%
Fixed effect model		6822	\$	0.61	[0.60; 0.63]	100.0%	
Random effects mode	ļ	1	$\diamond$	0.67	[0.63; 0.72]		100.0%
Heterogeneity: $I^2 = 91\%$ ,	τ <sup>-</sup> = 0.3158	3, p < 0.	01 ' ' '				
		0.	2 0.4 0.6 0.8	1			

b	Study	Events	Total					Proportion	95%-CI	Weight (fixed)	Weight (random)
	Ribas et al[137]	312	328				( <b>—</b>	0.95	[0.92; 0.97]	20.9%	26.6%
	Chung et al[136]	30	47 —					0.64	[0.49; 0.77]	14.9%	25.8%
	Calabrò et al[138]	26	29				֥	0.90	[0.73; 0.98]	3.7%	19.7%
	Maio et al[140]	329	380			_	• <u>•</u>	0.87	[0.83; 0.90]	60.6%	27.9%
	Fixed effect model		784				~	0.87	[0.84; 0.89]	100.0%	
	Random effects model				_			0.87	[0.72; 0.94]		100.0%
	Heterogeneity: $I^2 = 92\%$ , $\tau^2$	<sup>2</sup> = 0.8215	5, p < 0.01		I	I					
			0.5	0.6	0.7	0.8	0.9				

Figure 7 (a) Forest plot of pembrolizumab; and (b) tremelimumab for grade 1–5 adverse events (AEs).

that the incidence of AEs was 5.86% (95% CI: 0.0335– 0.1007, P < 0.1,  $I^2 = 88.9\%$ ). Seven articles reported the grade 3–5 AEs to durvalumab, and heterogeneity analysis showed greater statistical heterogeneity between the results of each study (P < 0.1,  $I^2 = 93.4\%$ ), so the random effects model was used for merging. Meta-analysis results showed the incidence of AEs in durvalumab was reported in six articles to be 13.43% (95% CI: 0.0715–0.2383, P < 0.1,  $I^2 = 93.4\%$ ). A total of 30 articles reported ipilimumab grade 3–5 AEs, and heterogeneity analysis showed larger statistical heterogeneity between the results of each study (P < 0.1,  $I^2 = 90.4\%$ ), so the random effects model was



**Figure 8** Funnel plot of PD-1 for grade 1–5 adverse events (AEs).

Woight

Woight

Study	Events	Total		Proportion	95%-CI	(fixed)	(random)
Ribas et al[9]	45	171	}	0.26	[0.20; 0.34]	2.8%	5.2%
Reck et al[16]	109	151		- 0.72	[0.64; 0.79]	2.6%	5.1%
Herbst et al[10]	80	309		0.26	[0.21; 0.31]	5.0%	5.7%
Plimack et al[18]	126	272	<del>3</del> <del>3</del>	0.46	[0.40; 0.52]	5.7%	5.8%
Shitara et al[31]	96	276	<u> </u>	0.35	[0.29; 0.41]	5.3%	5.7%
Cohen et al[33]	85	248	— <b>•</b>	0.34	[0.28; 0.41]	4.7%	5.6%
Mok et al[37]	252	615		0.41	[0.37; 0.45]	12.6%	6.1%
Weber et al[70]	32	102		0.31	[0.23; 0.41]	1.9%	4.7%
Borghaei et al[67]	144	290	i — • —	0.50	[0.44; 0.56]	6.2%	5.8%
Brahmer et al[68]	71	137		0.52	[0.43; 0.60]	2.9%	5.2%
Carbone et al[71]	133	270		0.49	[0.43; 0.55]	5.7%	5.8%
Ferris et al[74]	39	121		0.32	[0.24; 0.41]	2.2%	4.9%
Rittmeyer et al[79]	248	578	<b>+</b>	0.43	[0.39; 0.47]	12.0%	6.1%
Fehrenbacher et al[87]	55	143		0.38	[0.30; 0.47]	2.9%	5.2%
Powles et al[81]	189	443		0.43	[0.38; 0.47]	9.2%	6.0%
Barlesi et al[97]	180	365	· · · · ·	0.49	[0.44; 0.55]	7.7%	5.9%
Bang et al[121]	69	186	<u> </u>	0.37	[0.30; 0.44]	3.7%	5.4%
Ribas et al[137]	132	327		0.40	[0.35; 0.46]	6.7%	5.8%
Fixed effect model		5004	<b>*</b>	0.42	[0.40; 0.43]	100.0%	
Random effects model			$\diamond$	0.41	[0.37; 0.46]		100.0%
Heterogeneity: $I^2 = 89\%$ , $\tau$	$r^2 = 0.1220$	, <i>p</i> < 0	01 1 1 1				
		0	.2 0.3 0.4 0.5 0.6 0.7				



								Weight	Weight
a	Study	Events	Total			Proportion	95%-CI	(fixed)	(random)
	Weber et al[114]	208	453			0.46	[0.41; 0.51]	9.7%	3.4%
	Larkin et al[72]	85	311			0.27	[0.22; 0.33]	5.3%	3.3%
	Robert et al[5]	51	256			0.20	[0.15; 0.25]	3.5%	3.3%
	Ribas et al[137]	22	328	-		0.07	[0.04; 0.10]	1.8%	3.1%
	Small et al[112]	3	14			0.21	[0.05; 0.51]	0.2%	1.7%
	Weber et al[114]	12	88			0.14	[0.07; 0.23]	0.9%	2.8%
	Jeffrey et al[131]	22	57			0.39	[0.26; 0.52]	1.2%	2.9%
	Oday et al[132]	34	115			0.30	[0.21; 0.39]	2.1%	3.1%
	Wolchok et al[133]	23	214			0.11	[0.07; 0.16]	1.8%	3.1%
	Omid et al[126]	11	82			0.13	[0.07; 0.23]	0.8%	2.7%
	Slovin et al[113]	2	8			0.25	[0.03; 0.65]	0.1%	1.3%
	Slovin et al[113]	3	6		+	0.50	[0.12; 0.88]	0.1%	1.3%
	Slovin et al[113]	10	16	-		0.62	[0.35; 0.85]	0.3%	2.1%
	Yamazaki et al[115]	3	60	+		0.05	[0.01; 0.14]	0.2%	1.8%
	Eggermont et al[116]	196	471	-	- <b>·</b>	0.42	[0.37; 0.46]	9.9%	3.4%
	Ascierto et al[117]	66	362			0.18	[0.14; 0.23]	4.7%	3.3%
	Ascierto et al[117]	124	364	-		0.34	[0.29; 0.39]	7.1%	3.4%
	Beer et al[118]	158	399	-	•	0.40	[0.35; 0.45]	8.3%	3.4%
	Chesney et al[119]	33	95			0.35	[0.25; 0.45]	1.9%	3.1%
	Weber et al[120]	208	453			0.46	[0.41; 0.51]	9.7%	3.4%
	Bang et al[121]	13	57			0.23	[0.13; 0.36]	0.9%	2.8%
	Zimmer et al[122]	20	103			0.19	[0.12; 0.28]	1.4%	3.0%
	Weber et al[123]	10	20		+	- 0.50	[0.27; 0.73]	0.4%	2.3%
	Geoerger et al[124]	6	12				[0.21; 0.79]	0.3%	1.9%
	Hersh et al[125]	5	39			0.13	[0.04; 0.27]	0.4%	2.2%
	Chesney et al[119]	33	95			0.35	[0.25; 0.45]	1.9%	3.1%
	Postow et al[127]	11	46			0.24	[0.13; 0.39]	0.7%	2.7%
	Larkin et al[128]	85	311			0.27	[0.22; 0.33]	5.3%	3.3%
	Hodi et al[129]	58	120			0.48	[0.39; 0.58]	2.6%	3.2%
	Hodi et al[130]	30	131	i		0.23	0.16: 0.31	2.0%	3.1%
	Robert et al[5]	51	256			0.20	0.15: 0.25	3.5%	3.3%
	Camacho et al[134]	10	28			0.36	[0.19: 0.56]	0.6%	2.5%
	Camacho et al[134]	18	89			0.20	[0.12: 0.30]	1.2%	2.9%
	Chung et al[136]	.9	47			0.19	[0.09: 0.33]	0.6%	2.6%
	Calabrò et al[138]	4	29			0.14	[0.04: 0.32]	0.3%	2.0%
	Maio et al[140]	211	380			0.56	[0.50; 0.61]	8.1%	3.4%
	Fixed effect model		5915	\$		0.34	[0.32; 0.35]	100.0%	
	Random effects model			,		0.27	[0.23; 0.32]		100.0%
	Heterogeneity: $I^2 = 93\%$ , $\tau^2$	$^{2} = 0.4049$	), p < 0.	01					
			-	0.2 0	.4 0.6	0.8			

Figure 10 (a) Forest plot of CTLA-4; and (b) PD-1 for grade 3–5 adverse events (AEs).

used for the merger. Meta-analysis results showed the incidence rate of its AEs was 28.27% (95% CI: 0.2401–0.3297, P < 0.1,  $I^2 = 90.4\%$ ). A total of 25 articles reported grade 3–5 AEs to nivolumab. Heterogeneity analysis showed greater statistical heterogeneity among the results of each study (P < 0.1,  $I^2 = 55.1\%$ ), so the random effects model was used for the merger. Meta-analysis showed that the incidence of AEs was 15.72% (95% CI: 0.1368–0.1800, P < 0.1,  $I^2 = 55.1\%$ ). A total of 44 articles reported grade 3–5 AEs to pembrolizumab, and heterogeneity analysis showed a greater statistical heterogeneity between the results of each study (P < 0.1,  $I^2 = 52.94\%$ ), so the random effects model was used for consolidation. Meta-analysis showed that the incidence of AEs was 16.58% (95% CI:

0.1347–0.2025, P < 0.1,  $I^2 = 52.94\%$ ). Six articles reported grade 3–5 AEs to tremelimumab, and heterogeneity analysis showed a greater statistical heterogeneity between the results of each study (P < 0.1,  $I^2 = 97.0\%$ ), so the random effects model was used for the merger. Meta-analysis results showed that the AE rate was 22.04% (95% CI: 0.0812–0.4749, P < 0.1,  $I^2 = 97.0\%$ ).

Risk assessment of publication bias based on grade 3-5 adverse events in different ICIs in malignant tumors

All studies included in this meta-analysis reported grade 3-5 AEs. To fully reflect the situation, we performed a funnel plot analysis of the included papers. The points on the funnel plot were approximately symmetric, indicating that there was no publication bias. The *P* publication bias of

)	Study	Events	Total		Proportion	95%-CI	Weight (fixed)	Weight (random)	Figure 10	Continued.
	Bibas et al[9]	44	357	<b></b>	0.12	[0.09: 0.16]	3.0%	1.7%		
	Reck et al[16]	98	154		0.64	[0.56: 0.71]	2.8%	1.7%		
	Herbst et al[10]	41	682	<b>=</b>	0.06	[0.04: 0.08]	3.0%	1.7%		
	Plimack et al[18]	40	266		0.15	[0.11; 0.20]	2.6%	1.7%		
	Shitara et al[31]	42	294		0.14	[0.10; 0.19]	2.8%	1.7%		
	Cohen et al[33]	33	246		0.13	[0.09; 0.18]	2.2%	1.7%		
	Mok et al[37]	113	636	-	0.18	[0.15; 0.21]	7.2%	1.8%		
	Weber et al[70]	24	268		0.09	[0.06; 0.13]	1.7%	1.6%		
	Borghaei et al[67]	30	287		0.10	[0.07; 0.15]	2.1%	1.7%		
	Brahmer et al[68]	9	131		0.07	[0.03; 0.13]	0.7%	1.4%		
	Carbone et al[71]	47	267		0.18	[0.13; 0.23]	3.0%	1.7%		
	Ferris et al[74]	31	236	- <u>E</u> <sup>1</sup>	0.13	[0.09; 0.18]	2.1%	1.7%		
	Weber et al[114]	65	452		0.14	[0.11; 0.18]	4.3%	1.8%		
	Larkin et al[72]	51	316		0.16	[0.12; 0.21]	3.3%	1.7%		
	Robert et al[5]	37	556	<b>*</b> (	0.07	[0.05; 0.09]	2.7%	1.7%		
	Garon et al[6]	47	495	-	0.09	[0.07; 0.12]	3.3%	1.7%		
	Patnaik et al[7]	0	30		0.00	[0.00; 0.12]	0.0%	0.3%		
	Le et al[21]	17	41		0.41	[0.26; 0.58]	0.8%	1.5%		
	Shimizu et al[11]	4	10		0.40	[0.12; 0.74]	0.2%	0.9%		
	Nghiem et al[12]	4	26		0.15	[0.04; 0.35]	0.3%	1.0%		
	Ngniem et al[12]	5	32		0.16	[0.05; 0.33]	0.3%	1.1%		
	wuro et al[13]	5	39		0.13	[0.04; 0.27]	0.3%	1.2%		
	Goldborg of al[14]	10	00	10 10	0.17	[0.06; 0.29]	0.0%	1.4%		
	Plimack of al[19]	) 5	30		0.14	[0.05, 0.29]	0.3%	1.2%		
	Hui et al[19]	0 10	101		0.15	[0.06, 0.32]	0.3%	1.1%		
	Naova et al[3]	12	101		0.12	[0.00, 0.20]	0.0%	1.3%		
	Allev et al[43]	3	+2 25		0.19	[0.03: 0.34]	0.2%	0.9%		
	Bauml et al[44]	26	171	- <u>+</u>	0.12	[0.10: 0.21]	1.7%	1.6%		
	Wei et al[4]	15	25		0.60	[0.39: 0.79]	0.5%	1.3%		
	Ott et al[17]	4	25		0.16	[0.05: 0.36]	0.3%	1.0%		
	Ott et al[17]	4	24		0.17	[0.05: 0.37]	0.3%	1.0%		
	Ott et al[17]	2	24		0.08	[0.01: 0.27]	0.1%	0.8%		
	Schachter et al[22]	93	555		0.17	[0.14: 0.20]	6.0%	1.8%		
	Hsu et al[45]	8	27		0.30	[0.14: 0.50]	0.4%	1.3%		
	Balar et al[23]	58	370	-	0.16	[0.12; 0.20]	3.8%	1.7%		
	Adra et al[24]	6	12	· · · · · · · · · · · · · · · · · · ·	0.50	[0.21; 0.79]	0.2%	1.0%		
	Frenel et al[46]	5	24		0.21	[0.07; 0.42]	0.3%	1.1%		
	Cohen et al[26]	3	26		0.12	[0.02; 0.30]	0.2%	0.9%		
	Fuchs et al[27]	46	259	- <u>1.</u>	0.18	[0.13; 0.23]	2.9%	1.7%		
	Rugo et al[28]	4	25		0.16	[0.05; 0.36]	0.3%	1.0%		
	Eggermont et al[29]	36	514	<b>=</b>	0.07	[0.05; 0.10]	2.6%	1.7%		
	Zhu et al[30]	26	104		0.25	[0.17; 0.34]	1.5%	1.6%		
	Hansen et al[32]	4	23		0.17	[0.05; 0.39]	0.3%	1.0%		
	Adams et al[48]	8	84		0.10	[0.04; 0.18]	0.6%	1.4%		
	Varga et al[34]	1	26		0.04	[0.00; 0.20]	0.1%	0.5%		
	Shah et al[35]	15	121		0.12	[0.07; 0.20]	1.0%	1.5%		
	Levy et al[36]	27	49		0.55	[0.40; 0.69]	0.9%	1.5%		
	Yamamoto et al[54]	1	3		0.00	[0.00; 0.71]	0.0%	0.3%		
	Yamamoto et al[54]	1	5		0.20	[0.01; 0.72]	0.1%	0.4%		
	Vamamoto et al[54]	1	0		- 0.00	[0.00, 0.46]	0.0%	0.3%		
	Kang et al[79]	3/	330	+	0.33	[0.07.01/1]	2 /1%	1 7%		
	Motzer et al[60]	34 76	000 ⊿10		0.10	[0.07, 0.14]	2.4% 1 8%	1.7 %		
	l arkin et al[72]	51	313	-	0.19	[0 12. 0 21]	3.3%	1.0%		
	Long et al[58]	4	25		0.10	[0.05: 0.36]	0.3%	1.0%		
	Hamanishi et al[63]	4	10		0.40	[0.12; 0.74]	0.2%	0.9%		
	Hamanishi et al[63]	4	10		0.40	[0.12: 0.74]	0.2%	0.9%		
	Kudo et al[62]	11	65		0.17	[0.09; 0.28]	0.7%	1.4%		
	Maruyama et al[56]	4	17		0.24	[0.07; 0.50]	0.2%	1.0%		
	Nishio et al[60]	17	76		0.22	[0.14; 0.33]	1.0%	1.5%		
	Overman et al[57]	15	74	- 1: m 	0.20	[0.12; 0.31]	0.9%	1.5%		
	Rizvi et al[64]	20	117	- <u></u>	0.17	[0.11; 0.25]	1.3%	1.6%		
	Yamazaki et al[59]	3	24		0.12	[0.03; 0.32]	0.2%	0.9%		
	Younes et al[55]	20	80		0.25	[0.16; 0.36]	1.2%	1.6%		
	Ansell et al[66]	5	23		0.22	[0.07; 0.44]	0.3%	1.1%		
	Xu et al[141]	17	23		- 0.74	[0.52; 0.90]	0.3%	1.2%		
	Fang et al[146]	16	93		0.17	[0.10; 0.26]	1.0%	1.5%		
	Shi et al[148]	17	96	- <u>kon</u> 19 <sup>00</sup> 10	0.18	[0.11; 0.27]	1.1%	1.6%		
	Migden et al[149]	25	59		0.42	[0.30; 0.56]	1.1%	1.6%		
	Tang et al[142]	13	36		0.36	[0.21; 0.54]	0.6%	1.4%		
	Nie et al[145]	3	86	<b>—</b>	0.03	[0.01; 0.10]	0.2%	1.0%		
	Bang et al[38]	6	56		0.11	[0.04; 0.22]	0.4%	1.2%		
	Si et al[39]	9	103		0.09	[0.04; 0.16]	0.6%	1.4%		
	Unung et al[40]	12	98		0.12	[0.06; 0.20]	0.8%	1.5%		
	Shi et al[148]	17	96		0.18	[0.11; 0.27]	1.1%	1.6%		
	Fixed effect model		100/2	d:	0.16	[0 15. 0 17]	100 0%			
	Random effects model	1	10343	v.	0.10	[0.15; 0.20]	.00.0%	100.0%		
	Heterogeneity: $I^2 = 87\%$ , a	$r^2 = 0.3903$	s, p < 0.	1	0.11	[				
			•	0 0.2 0.4 0.6 0.8						

						Weight	Weight
а	Study	Events	Total	Proportion	95%-CI	(fixed)	(random)
	Rittmeyer et al[79]	90	609	0.15	[0.12; 0.18]	12.3%	4.3%
	Fehrenbacher et al[87]	16	142	0.11	[0.07; 0.18]	2.3%	3.9%
	Powles et al[81]	91	459	0.20	[0.16; 0.24]	11.7%	4.3%
	Barlesi et al[97]	35	393	0.09	[0.06; 0.12]	5.1%	4.2%
	Bang et al[121]	18	184		[0.06; 0.15]	2.6%	4.0%
	Peters et al[80]	81	659	0.12	[0.10; 0.15]	11.4%	4.3%
	Petrylak et al[82]	9	95	0.09	[0.04; 0.17]	1.3%	3.6%
	Colevas et al[86]	4	32		[0.04; 0.29]	0.6%	2.9%
	Horn et al[85]	10	89	0.11	[0.06; 0.20]	1.4%	3.7%
	Lukas et al[84]	3	16	0.19	[0.04; 0.46]	0.4%	2.6%
	Spigel et al[83]	25	137	0.18	[0.12; 0.26]	3.3%	4.1%
	McDermott et al[77]	12	65	0.18	[0.10; 0.30]	1.6%	3.8%
	Gulley et al[90]	3	184	- : 0.02	[0.00; 0.05]	0.5%	2.8%
	Dirix et al[93]	23	168	0.14	[0.09; 0.20]	3.2%	4.1%
	Chung et al[102]	13	150		[0.05; 0.14]	1.9%	3.9%
	Disis et al[101]	3	125		[0.00; 0.07]	0.5%	2.7%
	Kelly et al[95]	39	1738	0.02	[0.02; 0.03]	6.1%	4.2%
	Keilholz et al[100]	0	51		[0.00; 0.07]	0.1%	1.0%
	Hassan et al[99]	6	53	0.11	[0.04; 0.23]	0.9%	3.3%
	Le et al[98]	2	25	0.08	[0.01; 0.26]	0.3%	2.2%
	Antonia et al[104]	142	473	0.30	[0.26; 0.34]	15.9%	4.4%
	Yang et al[107]	23	68	0.34	[0.23; 0.46]	2.4%	4.0%
	Massard et al[103]	3	61		[0.01; 0.14]	0.5%	2.7%
	Segal et al[111]	6	62	0.10	[0.04; 0.20]	0.9%	3.3%
	Zandberg et al[110]	9	112	0.08	[0.04; 0.15]	1.3%	3.6%
	Siu et al[109]	8	67		[0.05; 0.22]	1.1%	3.5%
	Herbst et al[76]	35	277	0.13	[0.09; 0.17]	4.9%	4.2%
	Garassino et al[105]	40	444	0.09	[0.07; 0.12]	5.8%	4.2%
	Fixed effect model		6938	.√ 0.14	[0.13; 0.15]	100.0%	
	Random effects model			<u> </u>	[0.08; 0.14]		100.0%
	Heterogeneity: $I^2 = 92\%$ , $\tau$	$z^2 = 0.5527$	, p < 0	1 1 7 7 7			
				0.1 0.2 0.3 0.4			

b	Study	Events	Total		Proportion	95%-Cl	Weight (fixed)	Weight (random)
	Rittmeyer et al[79]	90	609		0.15	[0.12; 0.18]	24.1%	16.5%
	Fehrenbacher et al[87]	16	142		0.11	[0.07; 0.18]	4.5%	7.8%
	Powles et al[81]	91	459	— • —	0.20	[0.16; 0.24]	22.9%	16.3%
	Peters et al[80]	81	659	- + <u>1</u>	0.12	[0.10; 0.15]	22.3%	16.2%
	Petrylak et al[82]	9	95		0.09	[0.04; 0.17]	2.6%	5.3%
	Colevas et al[86]	4	32		0.12	[0.04; 0.29]	1.1%	2.6%
	Horn et al[85]	10	89		0.11	[0.06; 0.20]	2.8%	5.6%
	Lukas et al[84]	3	16	*	- 0.19	[0.04; 0.46]	0.8%	1.9%
	Spigel et al[83]	25	137		0.18	[0.12; 0.26]	6.4%	9.7%
	McDermott et al[77]	12	65		0.18	[0.10; 0.30]	3.1%	6.0%
	Herbst et al[76]	35	277		0.13	[0.09; 0.17]	9.6%	12.0%
	Fixed effect model		2580	\$	0.15	[0.14; 0.16]	100.0%	
	Random effects model			$\stackrel{\cdot}{\diamondsuit}$	0.14	[0.12; 0.17]		100.0%
	Heterogeneity: $I^2 = 50\%$ , $\tau^2$	$^{2} = 0.0385$	5, p = 0.	)3				
				0.1 0.2 0.3 0.4				



the 18 articles included in the conventional therapy study was >0.05, and no publication bias was found. All 36 studies included in CTLA-4 reported AEs, *P* publication bias was >0.05, and therefore no publication bias was found.

The *P* publication bias of the 28 articles included in the PD-L1 study was >0.05, and no publication bias was found. The *P* publication bias of the 76 articles included in the PD-1 study was >0.05, and no publication bias was found.



Figure 12 (a) Forest plot of avelumab; and (b) durvalumab for grade 3–5 adverse events (AEs).

There were 11 articles which reported that atezolizumab had a bias of grade 3-5, AE published bias was >0.05, and no publication bias was found. There were 10 articles which reported grade 3-5 AEs to avelumab, P publication bias was >0.05, and therefore no publication bias was found. A total of 7 articles reported grade 3-5 AEs to durvalumab, and P publication bias was unclear. We found 30 reports in the literature of grade 3-5 AEs to ipilimumab, P publication bias was >0.05, and therefore no publication bias was found. There were 25 articles on nivolumab grade 3-5 AEs, publication bias was >0.05, and no publication bias was found. A total of 44 articles reported grade 3-5 AEs to pembrolizumab, P publication bias was >0.05, and no publication bias was found. There were six articles in which grade 3-5 AEs to temilimumab were reported, and the P publication bias was unclear.

#### Discussion

This study compared 11 different ICI-related (grade 1-5 and 3-5) AEs, including 147 articles and 23 761 patients

(Table 1). There were 46 articles on pembrolizumab (n = 6598), 27 on nivolumab (n = 3576), 13 on atezolizumab (n = 2787), 12 on avelumab (n = 3213), 10 on durvalumab (n = 1780), 22 on ipilimumab (n = 4067), eight on tremelimumab (n = 1158), three on JS001 (n = 223), four on SHR-1210 (n = 178), one on sintilimab (n = 96), and one on cemiplimab (n = 85). The grade 1–5 AEs were: 83.81% (conventional therapy), 82.87% (CTLA-4), 71.89% (PD-1), and 58.95% (PD-L1). The rates in subanalysis 44.53% (avelumab), 66.63% group were: (durvalumab), 67.25% (pembrolizumab), 68.77% (atezolizumab), 76.25% (nivolumab), 82.18% (ipilimumab), and 86.78% (tremelimumab). The grade 3-5 AE rates were: 41.28% (conventional therapy), 27.22% (CTLA-4), 17.29% (PD-1), and 17.29% (PD-L1). The rates in subgroup analysis were: 5.86% (avelumab), 13.43% (durvalumab), 14.45% (atezolizumab), 15.72% (nivolumab), 16.58% (pembrolizumab), 22.04% (tremelimumab), and 28.27% (ipilimumab).

ICI therapy has only been approved for a short period of time in China, and the clinical data is still at the

а	Study	Events	Total		Proportion	95%-CI	Weight (fixed)	Weight (random)
	Weher et al[114]	208	453		0.46	[0 41 0 51]	11.2%	4 2%
	Larkin et al[72]	85	311		0.27	[0.22: 0.33]	6.1%	4.1%
	Robert et al[5]	51	256		0.20	[0.15; 0.25]	4.0%	4.0%
	Small et al[112]	3	14		0.21	[0.05; 0.51]	0.2%	1.8%
	Weber et al[114]	12	88	I	0.14	[0.07; 0.23]	1.0%	3.3%
	Jeffrey et al[131]	22	57		0.39	[0.26; 0.52]	1.3%	3.5%
	Oday et al[132]	34	115		0.30	[0.21; 0.39]	2.4%	3.8%
	Wolchok et al[133]	23	214		0.11	[0.07; 0.16]	2.0%	3.7%
	Omid et al[126]	11	82		0.13	[0.07; 0.23]	0.9%	3.2%
	Slovin et al[113]	2	8		0.25	[0.03; 0.05]	0.1%	1.3%
	Slovin et al[113]	10	16		- 0.50	[0.12, 0.00]	0.1%	2 30/
	Yamazaki et al[115]	3	60	+ !	0.02	[0.03, 0.03]	0.4%	2.0%
	Eggermont et al[116]	196	471		0.03	[0.37: 0.46]	11.3%	4.2%
	Ascierto et al[117]	66	362	+	0.18	[0.14: 0.23]	5.4%	4.1%
	Ascierto et al[117]	124	364		0.34	[0.29; 0.39]	8.1%	4.2%
	Beer et al[118]	158	399		0.40	[0.35; 0.45]	9.5%	4.2%
	Chesney et al[119]	33	95		0.35	[0.25; 0.45]	2.1%	3.8%
	Weber et al[120]	208	453		0.46	[0.41; 0.51]	11.2%	4.2%
	Bang et al[121]	13	57		0.23	[0.13; 0.36]	1.0%	3.3%
	Zimmer et al[122]	20	103		0.19	[0.12; 0.28]	1.6%	3.6%
	Weber et al[123]	10	20		0.50	[0.27; 0.73]	0.5%	2.6%
	Geoerger et al[124]	6	12		0.50	[0.21; 0.79]	0.3%	2.0%
	Hersh et al[125]	5	39		0.13	[0.04; 0.27]	0.4%	2.4%
	Direstiev et al[119]	33	95		0.35	[0.25; 0.45]	2.1%	3.8%
	l arkin et al[128]	85	311		0.24	[0.13, 0.39]	6.1%	3.1 /o 4 1%
	Hodi et al[120]	58	120		0.27	[0.39: 0.58]	3.0%	3.9%
	Hodi et al[120]	30	131		0.23	[0.16: 0.31]	2.3%	3.8%
	Robert et al[5]	51	256		0.20	[0.15; 0.25]	4.0%	4.0%
	Fixed effect model Random effects model	2	5014		0.33	[0.32; 0.34] [0.24; 0.33]	100.0%	 100.0%
	Heterogeneity: $T = 90\%$ , $\tau$	- = 0.2921	, p < 0.	0.2 0.4 0.6 0.8				
b	Study	= 0.2921 Events	, <i>p</i> < 0. <b>Total</b>	0.2 0.4 0.6 0.8	Proportion	95%-CI	Weight (fixed)	Weight (random)
b	Study Weber et al[70]	- = 0.2921 Events 24	, <i>p</i> < 0. <b>Total</b> 268	0.2 0.4 0.6 0.8	Proportion	<b>95%–Cl</b> [0.06; 0.13]	Weight (fixed) 4.9%	Weight (random) 5.8%
b	Study Weber et al[70] Borghaei et al[67]	Events 24 30	, <i>p</i> < 0. <b>Total</b> 268 287	0.2 0.4 0.6 0.8	<b>Proportion</b> 0.09 0.10	<b>95%–Cl</b> [0.06; 0.13] [0.07; 0.15]	Weight (fixed) 4.9% 6.1%	Weight (random) 5.8% 6.3%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68]	Events 24 30 9	, <i>p</i> < 0. <b>Total</b> 268 287 131	0.2 0.4 0.6 0.8	Proportion 0.09 0.10 0.07	<b>95%–Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13]	Weight (fixed) 4.9% 6.1% 1.9%	Weight (random) 5.8% 6.3% 3.6%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71]	Events 24 30 9 47	, <i>p</i> < 0. <b>Total</b> 268 287 131 267 202	0.2 0.4 0.6 0.8	Proportion 0.09 0.10 0.07 0.18	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23]	Weight (fixed) 4.9% 6.1% 1.9% 8.8%	Weight (random) 5.8% 6.3% 3.6% 7.0%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74]	Events 24 30 9 47 31	, <i>p</i> < 0. <b>Total</b> 268 287 131 267 236 450	0.2 0.4 0.6 0.8	Proportion 0.09 0.10 0.07 0.18 0.13	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23] [0.09; 0.18]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[14] Larkin et al[72]	Events 24 30 9 47 31 65	, <i>p</i> < 0. <b>Total</b> 268 287 131 267 236 452 316	0.2 0.4 0.6 0.8	Proportion 0.09 0.10 0.07 0.18 0.13 0.14	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23] [0.09; 0.18] [0.12; 0.21]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.6% 7.2%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[114] Larkin et al[72] Yamamoto, et al[54]	Events 24 30 9 47 31 65 51 0	, <i>p</i> < 0. <b>Total</b> 268 287 131 267 236 452 316 3		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.16 0.00	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.13; 0.23] [0.09; 0.18] [0.11; 0.18] [0.12; 0.21] [0.00; 0.71]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 9.7% 0.1%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.6% 7.2% 0.3%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[14] Larkin et al[72] Yamamoto et al[54]	Events 24 30 9 47 31 65 51 0 1	, <i>p</i> < 0. <b>Total</b> 268 287 131 267 236 452 316 5		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.16 0.00 0.20	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.13; 0.23] [0.13; 0.23] [0.11; 0.18] [0.12; 0.21] [0.00; 0.71] [0.01: 0 72]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 9.7% 0.1% 0.2%	Weight (random) 5.8% 6.3% 7.0% 6.3% 7.6% 7.2% 0.3% 0.5%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[14] Larkin et al[72] Yamamoto et al[54] Yamamoto et al[54]	Events 24 30 9 47 31 65 51 0 1 0	, <i>p</i> < 0. <b>Total</b> 268 287 131 267 236 452 316 5 6		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.16 0.00 0.20 0.00	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23] [0.09; 0.18] [0.11; 0.18] [0.12; 0.21] [0.00; 0.71] [0.00; 0.46]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 9.7% 0.1% 0.2% 0.1%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.6% 7.2% 0.3% 0.5% 0.3%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[14] Larkin et al[72] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54]	Events 24 30 9 47 31 65 51 0 1 0 1 0 1	, <i>p</i> < 0. <b>Total</b> 268 287 131 267 236 452 316 3 5 6 3 3		Proportion 0.09 0.10 0.13 0.13 0.14 0.16 0.00 0.20 0.00 0.33	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.09; 0.18] [0.12; 0.21] [0.01; 0.72] [0.00; 0.71] [0.01; 0.72] [0.00; 0.46] [0.01; 0.91]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 9.7% 0.1% 0.2% 0.1% 0.2%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 6.3% 0.3% 0.5% 0.3% 0.3%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[114] Larkin et al[72] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54]	Events 24 30 9 47 31 655 51 0 1 0 1 34	, <i>p</i> < 0. <b>Total</b> 268 287 131 267 236 452 316 3 5 6 3 330		Proportion 0.09 0.10 0.13 0.13 0.14 0.16 0.00 0.20 0.00 0.33 0.10	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.09; 0.18] [0.11; 0.18] [0.12; 0.21] [0.00; 0.71] [0.00; 0.46] [0.01; 0.91] [0.07; 0.14]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 9.7% 0.1% 0.2% 0.1% 0.2% 6.9%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.6% 7.2% 0.3% 0.5% 0.3% 0.4% 6.6%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[114] Larkin et al[72] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Motzer et al[69]	Events 24 30 9 47 31 65 51 0 1 0 1 34 76	, <i>p</i> < 0. <b>Total</b> 268 287 131 267 236 452 316 3 3 3 330 410		Proportion 0.09 0.10 0.13 0.13 0.14 0.16 0.00 0.20 0.00 0.33 0.10 0.19	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.09; 0.18] [0.11; 0.23] [0.00; 0.71] [0.00; 0.71] [0.01; 0.72] [0.00; 0.46] [0.01; 0.91] [0.07; 0.14] [0.15; 0.23]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 0.1% 0.2% 0.1% 0.2% 6.9% 14.0%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.6% 7.2% 0.3% 0.5% 0.3% 0.4% 6.6% 7.8%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[74] Yamamoto et al[72] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Kang et al[73] Motzer et al[69] Larkin et al[72]	Events 24 30 9 47 31 65 51 0 1 0 1 34 76 51	, <i>p</i> < 0. <b>Total</b> 268 287 131 267 236 452 316 3 3 330 410 313		Proportion 0.09 0.10 0.7 0.18 0.13 0.14 0.16 0.00 0.20 0.00 0.20 0.00 0.20 0.00 0.20 0.00 0.19 0.16	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23] [0.11; 0.18] [0.12; 0.21] [0.00; 0.71] [0.00; 0.74] [0.00; 0.46] [0.17; 0.23] [0.12; 0.21]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 9.7% 0.1% 0.2% 0.1% 0.2% 6.9% 14.0% 9.7%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.2% 0.3% 0.5% 0.3% 0.5% 0.3% 0.4% 6.6% 7.8% 7.2%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[114] Larkin et al[72] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Kang et al[73] Motzer et al[69] Larkin et al[72] Long et al[58]	Events 24 30 9 47 31 65 51 0 1 0 1 34 766 51 4	, <i>p</i> < 0. <b>Total</b> 268 287 131 267 236 452 316 3 3 330 410 313 25		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.10 0.20 0.20 0.20 0.00 - 0.33 0.10 0.19 0.16 0.16	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23] [0.09; 0.18] [0.11; 0.18] [0.12; 0.21] [0.00; 0.71] [0.00; 0.46] [0.01; 0.91] [0.07; 0.14] [0.15; 0.23] [0.12; 0.21] [0.05; 0.36]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 9.7% 0.1% 0.2% 0.1% 0.2% 6.9% 14.0% 9.7% 0.8%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.6% 7.2% 0.3% 0.5% 0.3% 0.4% 6.6% 7.8% 7.2% 1.9%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[14] Larkin et al[72] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Kang et al[73] Motzer et al[69] Larkin et al[72] Long et al[58] Hamanishi et al[63]	Events 24 30 9 47 31 65 51 0 1 34 76 51 4 4 4	, p < 0. <b>Total</b> 268 287 131 267 236 452 316 3 3300 410 313 25 10		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.16 0.00 0.20 0.00 0.20 0.00 0.10 0.19 0.16 0.16 0.16 0.40	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23] [0.09; 0.18] [0.11; 0.18] [0.12; 0.21] [0.00; 0.71] [0.01; 0.72] [0.00; 0.46] [0.01; 0.91] [0.07; 0.14] [0.15; 0.23] [0.12; 0.24] [0.05; 0.36] [0.12; 0.74]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 9.7% 0.1% 0.2% 6.9% 14.0% 9.7% 0.8% 0.5%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.2% 0.3% 0.5% 0.3% 0.4% 6.6% 7.2% 7.2% 1.9% 1.4%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[67] Carbone et al[71] Ferris et al[74] Weber et al[71] Yamamoto et al[74] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Kang et al[73] Motzer et al[69] Larkin et al[72] Long et al[58] Hamanishi et al[63] Hamanishi et al[63]	Events 24 30 9 47 311 65 51 0 1 34 76 51 4 4 4 4 4	, p < 0. <b>Total</b> 268 287 131 267 316 330 410 313 330 410 313 25 10 10 20 20 20 20 20 20 20 20 20 2		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.16 0.20 0.20 0.00 0.20 0.00 0.20 0.00 0.10 0.19 0.16 0.16 0.10 0.20 0.20 0.00 0.20	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23] [0.09; 0.18] [0.11; 0.18] [0.12; 0.21] [0.00; 0.71] [0.01; 0.72] [0.00; 0.46] [0.01; 0.91] [0.07; 0.14] [0.15; 0.23] [0.12; 0.74] [0.12; 0.74] [0.12; 0.74]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 0.2% 0.1% 0.2% 0.1% 0.2% 6.9% 14.0% 9.7% 0.5% 0.5%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.6% 7.2% 0.3% 0.5% 0.3% 0.5% 0.3% 0.4% 6.6% 7.8% 7.2% 1.9% 1.4%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[74] Weber et al[74] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Kang et al[73] Motzer et al[69] Larkin et al[72] Long et al[58] Hamanishi et al[63] Hamanishi et al[63] Kudo et al[62]	Events 24 30 9 47 31 65 51 0 1 34 76 51 4 4 4 4 1 1	, p < 0. <b>Total</b> 268 287 131 267 316 330 410 313 255 10 10 655 17		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.16 0.20 0.00 0.20 0.00 0.33 0.10 0.19 0.16 0.16 0.40 0.40 0.40 0.40 0.40 0.40 0.52	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23] [0.09; 0.18] [0.11; 0.18] [0.12; 0.21] [0.00; 0.74] [0.00; 0.46] [0.07; 0.14] [0.07; 0.14] [0.15; 0.23] [0.12; 0.74] [0.05; 0.36] [0.12; 0.74] [0.12; 0.74] [0.09; 0.28]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 9.7% 0.1% 0.2% 0.1% 0.2% 0.9% 14.0% 9.7% 0.5% 0.5% 0.5%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 0.3% 0.5% 0.3% 0.5% 0.3% 0.5% 0.3% 0.5% 0.3% 0.4% 6.6% 7.8% 7.2% 1.9% 1.4% 3.8%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[74] Weber et al[74] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Kang et al[73] Motzer et al[69] Larkin et al[72] Long et al[58] Hamanishi et al[63] Hamanishi et al[63] Kudo et al[62] Maruyama et al[56]	Events 24 30 9 47 31 655 51 0 1 34 76 51 4 4 4 4 11 4 17 24 24 30 9 47 31 51 0 1 34 76 51 4 4 4 4 4 4 4 4 4 51 51 51 51 51 51 51 51 51 51	, p < 0. <b>Total</b> 268 287 131 267 236 452 316 330 410 313 25 6 330 410 313 25 10 10 65 77 76		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.16 0.00 0.20 0.00 0.00 0.33 0.10 0.19 0.16 0.40 0.40 0.40 0.40 0.40 0.40 0.77 0.24 0.20 0.20 0.00 0.00 0.20 0.00 0.20 0.00 0.20 0.00 0.20 0.00 0.20 0.00 0.20 0.00 0.10 0.12 0.00 0.00 0.00 0.10 0.10 0.10 0.10 0.10 0.10 0.12	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.09; 0.18] [0.11; 0.23] [0.12; 0.21] [0.00; 0.71] [0.00; 0.46] [0.01; 0.91] [0.07; 0.14] [0.07; 0.14] [0.15; 0.23] [0.12; 0.21] [0.05; 0.36] [0.12; 0.74] [0.12; 0.74] [0.09; 0.28] [0.07; 0.50]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 0.1% 0.2% 0.1% 0.2% 0.2% 0.2% 0.8% 0.5% 2.1% 0.5% 2.1%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.6% 7.2% 0.3% 0.5% 0.3% 0.5% 0.3% 0.5% 0.3% 0.4% 6.6% 7.2% 1.9% 1.4% 3.8% 1.4%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[114] Larkin et al[72] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[69] Larkin et al[72] Long et al[73] Motzer et al[69] Larkin et al[72] Long et al[73] Hamanishi et al[63] Hamanishi et al[63] Kudo et al[62] Maruyama et al[57]	Events 24 30 9 47 31 655 51 0 1 34 76 51 4 4 4 11 4 17 15	, ρ < 0. <b>Total</b> 268           287           131           267           316           3           452           316           3           3300           410           313           255           100           65           17           766           74		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.16 0.00 0.20 0.00 0.33 0.10 0.19 0.16 0.40 0.40 0.40 0.40 0.40 0.42 0.22 0.20	<b>95%-Cl</b> [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.09; 0.18] [0.11; 0.23] [0.12; 0.21] [0.00; 0.71] [0.00; 0.46] [0.01; 0.72] [0.07; 0.14] [0.07; 0.14] [0.07; 0.14] [0.15; 0.23] [0.12; 0.21] [0.12; 0.74] [0.12; 0.74] [0.12; 0.74] [0.12; 0.74] [0.12; 0.74] [0.12; 0.74] [0.12; 0.74] [0.12; 0.74] [0.12; 0.23]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 0.1% 0.2% 0.1% 0.2% 0.1% 0.2% 0.8% 0.5% 2.1% 0.5% 2.1% 0.7% 3.0%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.6% 7.2% 0.3% 0.4% 6.6% 7.8% 7.2% 1.9% 1.4% 1.4% 3.8% 1.7% 4.7%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[114] Larkin et al[72] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Kang et al[73] Motzer et al[69] Larkin et al[72] Long et al[58] Hamanishi et al[63] Hamanishi et al[63] Maruyama et al[57] Dizvi et al[64]	Events 24 30 9 47 31 65 51 0 1 34 76 51 4 4 4 11 4 17 52 20 1 1 1 1 1 1 1 1 1 1 1 1 1	, p < 0. <b>Total</b> 268 287 131 267 236 452 316 3300 410 313 25 10 010 65 17 76 74 117		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.16 0.00 0.20 0.00 0.20 0.33 0.10 0.19 0.16 0.16 0.40 0.40 0.40 0.40 0.40	95%-Cl [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23] [0.09; 0.18] [0.11; 0.18] [0.00; 0.71] [0.00; 0.72] [0.00; 0.46] [0.01; 0.72] [0.00; 0.46] [0.07; 0.14] [0.15; 0.23] [0.12; 0.74] [0.12; 0.74] [0.09; 0.28] [0.07; 0.50] [0.14; 0.33] [0.12; 0.31] [0.11; 0.32]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 9.7% 0.1% 0.2% 6.9% 0.1% 0.2% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 0.3% 0.5% 0.3% 0.5% 0.3% 0.4% 6.6% 7.2% 1.9% 1.4% 1.4% 3.8% 1.7% 4.7% 4.7%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[114] Larkin et al[72] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Kang et al[72] Long et al[69] Larkin et al[72] Long et al[69] Hamanishi et al[63] Hamanishi et al[63] Hamanishi et al[63] Maruyama et al[56] Nishio et al[60] Overman et al[57] Rizvi et al[64] Yamazaki et al[59]	Events 24 30 9 47 31 65 51 0 1 0 1 34 76 51 4 4 4 4 111 4 17 15 20 3	, p < 0. <b>Total</b> 268 287 131 267 236 452 316 452 316 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 -		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.16 0.00 0.20 0.00 0.33 0.10 0.19 0.16 0.16 0.40 0.40 0.40 0.40 0.40 0.40 0.41 0.42 0.22 0.20 0.77 0.24 0.22 0.20 0.77 0.24 0.22 0.20 0.77 0.18 0.13 0.14 0.13 0.14 0.16 0.00 0.20 0.20 0.00 0.19 0.22 0.20 0.40 0.19 0.19 0.19 0.19 0.16 0.40 0.40 0.40 0.19 0.19 0.19 0.19 0.19 0.22 0.20 0.40 0.19 0.19 0.22 0.20 0.19 0.19 0.22 0.20 0.19 0.19 0.19 0.22 0.20 0.19 0.19 0.22	95%-Cl [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23] [0.09; 0.18] [0.11; 0.18] [0.01; 0.21] [0.00; 0.71] [0.00; 0.74] [0.01; 0.21] [0.05; 0.36] [0.12; 0.74] [0.05; 0.36] [0.12; 0.74] [0.09; 0.28] [0.07; 0.50] [0.14; 0.33] [0.12; 0.31] [0.11; 0.25] [0.03; 0.32]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 9.7% 0.1% 0.2% 6.9% 14.0% 9.7% 0.8% 0.5% 0.5% 2.1% 3.0% 2.7% 3.0%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.2% 0.3% 0.5% 0.3% 0.4% 6.6% 7.2% 1.9% 1.4% 1.4% 3.8% 1.7% 4.7% 4.7% 4.4% 5.2%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[71] Farris et al[74] Wamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Kang et al[72] Larkin et al[69] Larkin et al[69] Larkin et al[69] Hamanishi et al[63] Hamanishi et al[63] Hamanishi et al[63] Maruyama et al[57] Rizvi et al[64] Yamazaki et al[59] Younes et al[55]	Events 24 30 9 47 31 65 51 0 1 34 76 51 4 4 4 4 11 4 17 15 20 3 20	, p < 0. <b>Total</b> 268 287 131 267 316 330 410 313 330 410 10 65 10 10 65 17 76 74 117 24 80		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.16 0.00 0.20 0.00 0.20 0.00 0.20 0.00 0.10 0.19 0.16 0.16 0.40 0.40 0.40 0.40 0.41 0.22 0.20 0.17 0.22 0.20 0.21 0.22 0.20 0.21 0.22 0.20 0.22 0.20 0.22 0.25	95%-Cl [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23] [0.09; 0.18] [0.11; 0.18] [0.12; 0.21] [0.00; 0.71] [0.01; 0.72] [0.00; 0.46] [0.01; 0.91] [0.07; 0.14] [0.15; 0.23] [0.12; 0.21] [0.05; 0.36] [0.12; 0.74] [0.07; 0.50] [0.12; 0.31] [0.11; 0.25] [0.03; 0.32] [0.12; 0.31] [0.11; 0.25] [0.03; 0.32]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 9.7% 0.1% 0.2% 6.9% 14.0% 9.7% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.2% 0.3% 0.5% 0.3% 0.4% 6.6% 7.2% 1.9% 1.4% 1.4% 3.8% 1.7% 4.7% 4.7% 4.4% 5.2% 1.5%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[114] Larkin et al[72] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Kang et al[73] Motzer et al[69] Larkin et al[72] Long et al[58] Hamanishi et al[63] Hamanishi et al[63] Maruyama et al[56] Nishio et al[60] Overman et al[57] Rizvi et al[64] Yamazaki et al[59] Younes et al[56]	Events 24 30 9 47 31 65 51 0 1 34 76 51 4 4 4 4 111 4 17 15 20 3 20 5	, p < 0. <b>Total</b> 268 287 131 267 236 452 316 452 316 3 , 5 , 6 , 3 , 3300 410 517 76 74 117 24 80 23		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.10 0.20 0.20 0.00 0.33 0.10 0.19 0.16 0.16 0.40 0.40 0.40 0.40 0.40 0.22 0.20 0.17 0.24 0.22 0.20	95%-Cl [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.13; 0.23] [0.09; 0.18] [0.11; 0.18] [0.12; 0.21] [0.00; 0.71] [0.00; 0.46] [0.01; 0.91] [0.07; 0.14] [0.15; 0.23] [0.12; 0.74] [0.05; 0.36] [0.12; 0.74] [0.09; 0.28] [0.07; 0.50] [0.14; 0.33] [0.12; 0.31] [0.12; 0.31] [0.13; 0.32] [0.03; 0.32] [0.16; 0.36] [0.07; 0.44]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 0.1% 0.2% 6.9% 0.1% 0.2% 6.9% 14.0% 9.7% 0.8% 0.5% 0.5% 2.1% 3.0% 2.7% 3.0% 2.7% 3.0% 2.7% 3.0%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.2% 0.3% 0.5% 0.3% 0.4% 6.6% 7.2% 1.9% 1.4% 1.4% 1.4% 3.8% 1.7% 4.7% 4.7% 4.5.2% 0.5.2% 0.5.2% 0.5.2% 0.5.2% 0.5.2%
b	Study Weber et al[70] Borghaei et al[67] Brahmer et al[68] Carbone et al[71] Ferris et al[74] Weber et al[74] Weber et al[74] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Yamamoto et al[54] Kang et al[73] Motzer et al[69] Larkin et al[72] Long et al[58] Hamanishi et al[63] Hamanishi et al[63] Kudo et al[62] Maruyama et al[57] Rizvi et al[64] Yamazaki et al[59] Younes et al[55] Ansell et al[66] Fixed effect model Random effects model	Events 24 30 9 47 31 65 51 0 1 34 76 51 4 4 4 11 4 17 15 20 3 20 5	ρ < 0. <b>Total</b> 268           287           131           267           316           3           452           316           3           313           255           10           65           10           65           17           76           74           117           24           80           23 <b>3548</b>		Proportion 0.09 0.10 0.07 0.18 0.13 0.14 0.16 0.00 0.20 0.00 0.33 0.10 0.19 0.16 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.41 0.25 0.22 0.15 0.15 0.16	95%-Cl [0.06; 0.13] [0.07; 0.15] [0.03; 0.13] [0.09; 0.18] [0.12; 0.21] [0.00; 0.71] [0.00; 0.71] [0.00; 0.46] [0.01; 0.91] [0.07; 0.14] [0.07; 0.14] [0.15; 0.23] [0.12; 0.71] [0.05; 0.36] [0.12; 0.74] [0.12; 0.74] [0.12; 0.74] [0.12; 0.74] [0.12; 0.31] [0.11; 0.25] [0.03; 0.32] [0.16; 0.36] [0.07; 0.44] [0.14; 0.17] [0.14; 0.18]	Weight (fixed) 4.9% 6.1% 1.9% 8.8% 6.1% 12.6% 0.1% 0.2% 0.1% 0.2% 0.2% 0.2% 0.2% 0.5% 2.1% 0.5% 2.1% 0.5% 2.1% 0.5% 2.1% 0.6% 3.7% 0.6% 3.4% 0.9%	Weight (random) 5.8% 6.3% 3.6% 7.0% 6.3% 7.2% 0.3% 0.5% 0.3% 0.4% 6.6% 7.2% 1.9% 1.4% 3.8% 1.7% 4.4% 5.2% 1.5% 5.0% 2.1%



							Weight	Weight
Study	Events	Total			Proportion	95%-CI	(fixed)	(random)
Ribas et al[9]	44	357			0.12	[0.09: 0.16]	5.0%	2.8%
Reck et al[16]	98	154			0.64	[0.56: 0.71]	4.6%	2.8%
Herbst et al[10]	41	682	+		0.06	[0.04: 0.08]	5.0%	2.8%
Plimack et al[18]	40	266			0.15	[0.11: 0.20]	4.4%	2.8%
Shitara et al[31]	42	294			0.14	[0.10: 0.19]	4.6%	2.8%
Cohen et al[33]	33	246			0.13	[0.09: 0.18]	3.7%	2.8%
Mok et al[37]	113	636	·:		0.18	[0.15; 0.21]	12.0%	2.9%
Robert et al[5]	37	556	+		0.07	[0.05; 0.09]	4.5%	2.8%
Garon et al[6]	47	495	-		0.09	[0.07; 0.12]	5.5%	2.8%
Patnaik et al[7]	0	30	<b>└──</b> ¦		0.00	[0.00; 0.12]	0.1%	0.6%
Le et al[21]	17	41	н. Н		0.41	[0.26; 0.58]	1.3%	2.5%
Shimizu et al[11]	4	10		+	0.40	[0.12: 0.74]	0.3%	1.6%
Nghiem et al[12]	4	26	+		0.15	[0.04: 0.35]	0.4%	1.9%
Nghiem et al[12]	5	32			0.16	[0.05: 0.33]	0.5%	2.0%
Muro et al[13]	5	39		-	0.13	[0.04; 0.27]	0.6%	2.1%
Seiwert et al[14]	10	60		_	0.17	[0.08: 0.29]	1.1%	2.4%
Goldberg et al[15]	5	36		_	0.14	[0.05: 0.29]	0.6%	2.0%
Plimack et al[18]	5	33			0.15	[0.05: 0.32]	0.5%	2.0%
Hui et al[19]	12	101	<u>E</u>		0.12	[0.06: 0.20]	1.4%	2.5%
Naova et al[3]	8	42			0.19	[0.09: 0.34]	0.8%	2.3%
Allev et al[43]	3	25			0.12	[0.03: 0.31]	0.3%	1.7%
Bauml et al[44]	26	171			0.15	[0.10: 0.21]	2.8%	2.7%
Wei et al[4]	15	25	0		- 0.60	[0.39: 0.79]	0.8%	2.2%
Ott et al[17]	4	25	¥		0.16	[0.05: 0.36]	0.4%	1.9%
Ott et al[17]	4	24			0.17	[0.05: 0.37]	0.4%	1.9%
Ott et al[17]	2	24		-	0.08	[0.01: 0.27]	0.2%	1.4%
Schachter et al[22]	93	555	1.		0.17	[0.14: 0.20]	10.0%	2.9%
Hsu et al[45]	8	27	1		0.30	[0.14: 0.50]	0.7%	2.2%
Balar et al[23]	58	370	·:		0.16	[0.12: 0.20]	6.3%	2.8%
Adra et al[24]	6	12		+	- 0.50	[0.21: 0.79]	0.4%	1.8%
Frenel et al[46]	5	24	î		0.21	[0.07: 0.42]	0.5%	2.0%
Cohen et al[26]	3	26		_	0.12	[0.02: 0.30]	0.3%	1.7%
Fuchs et al[27]	46	259			0.18	[0.13; 0.23]	4.9%	2.8%
Rugo et al[28]	4	25	¥		0.16	[0.05: 0.36]	0.4%	1.9%
Eggermont et al[29]	36	514	<b>—</b>		0.07	[0.05; 0.10]	4.3%	2.8%
Zhu et al[30]	26	104	C		0.25	[0.17: 0.34]	2.5%	2.7%
Hansen et al[32]	4	23			0.17	[0.05: 0.39]	0.4%	1.9%
Adams et al[48]	8	84	_		0.10	[0.04: 0.18]	0.9%	2.3%
Varga et al[34]	1	26			0.04	[0.00: 0.20]	0.1%	1.0%
Shah et al[35]	15	121			0.12	[0.00; 0.20]	1 7%	2.6%
Levy et al[36]	27	49			0.55	[0.40: 0.69]	1.6%	2.5%
Bang et al[38]	-1	56			0.00	[0.10, 0.00]	0.7%	2.2%
Si et al[39]	9	103			0.09	[0.04:0.16]	1 1%	2.4%
Chung et al[40]	12	98	C		0.00	[0.06: 0.20]	1 4%	2.5%
onding of all+o]	12	00	10 10 10		0.12	[0.00, 0.20]	1.470	2.070
Fixed effect model		6906	0		0.16	[0.15; 0.17]	100.0%	
Random effects model			<u> </u>		0.17	[0.13; 0.20]		100.0%
Heterogeneity: $I^2 = 90\%$ , $\tau$	<sup>2</sup> = 0.5294	, p < 0	.01					
		(	0.2	0.4 0.6				

Figure 14 Forest plot of pembrolizumab for grade 3–5 adverse events (AEs).

collection stage. Reports of relevant domestic AEs are rare and cannot be combined. There have been three studies for JS001 which included 223 patients<sup>143–145</sup>. In the first study, 23 patients with advanced neuroendocrine tumors were included. Grade 1–5 AEs were not reported, and grade 3 AEs occurred in two patients (9%). There were no patients with grade 4 AEs. In the second study, 48 patients with nasopharyngeal carcinoma were enrolled. Of the 48 patients, 46 (96%) had mostly grade 1 or 2 AEs. A total of 17 cases (35%) had grade 3 or above AEs. However, it was not explicitly reported in the study whether all were AEs caused by treatment. In the third study, 36 patients with advanced melanoma or urinary tumors were enrolled, and 36 (100%) had grade 1–5 AEs, and the incidence of grade 3 and grade 3 AEs was 36%. SHR-1210 included four studies and 178 patients<sup>146–149</sup>. The study involved classic

Study	Events	Total		Proportion	95%-CI	Weight (fixed)	Weight (random)
Ribas et al[137]	22	328 -	-	0.07	[0.04; 0.10]	14.1%	17.2%
Camacho et al[134]	10	28		0.36	[0.19; 0.56]	4.4%	16.4%
Camacho et al[134]	18	89		0.20	[0.12; 0.30]	9.8%	17.0%
Chung et al[136]	9	47		0.19	[0.09; 0.33]	5.0%	16.5%
Calabrò et al[138]	4	29 -		0.14	[0.04; 0.32]	2.4%	15.4%
Maio et al[140]	211	380		0.56	[0.50; 0.61]	64.3%	17.5%
Fixed effect model		901	🔷	0.38	[0.34; 0.42]	100.0%	
Random effects mode Heterogeneity: $I^2 = 97\%$ ,	el τ <sup>2</sup> = 1.9977	', p < 0.0	01	0.22	[0.08; 0.47]		100.0%
			01 02 03 04 05 0	6			

Figure 15 Forest plot of tremelimumab for grade 3–5 adverse events (AEs).

Table 1 Adverse reaction rate of different ICIs

Drug type	Pembrolizumab	Nivolumab	Atezolizumab	Avelumab	Durvalumab	Ipilimumab	Tremelimumab
No. of patients	6598	3576	2787	3213	1780	4067	1158
No. of studies	46	27	13	12	10	22	8
Grade 1–5 AE	67.25%	76.25%	68.77%	44.53%	66.63%	82.18%	86.78%
Grade 35 AE	16.58%	15.72%	14.45%	5.86%	13.43%	28.27%	22.04%

AE, adverse event.

Hodgkin's lymphoma, gastric/gastroesophageal junction adenocarcinoma, nasopharyngeal carcinoma, and solid tumor.

Of the 178 patients, 169 (94.9%) had grade 1–5 AEs, and 24 (13.5%) had grade 3–5 AEs. Sintilimab was included in only one study<sup>148</sup> and out of 96 patients with classic Hodgkin's lymphoma, 89 (93%) had grade 1–5 AEs and 17 (18%) had grade 3–5 AEs. There was only one study on cemiplimab included (grade 1 and 2),<sup>149</sup> and out of a total of 85 patients with cutaneous squamous cell carcinoma, 59 (69.4%) had grade 1–5 AEs, and 12 (14.1%) had grade 3–5 AEs.

The irAEs from ICI therapy are mainly caused by immune activation against the autoimmune system. Other secondary toxicity may be due to changes in immune cell function and cytokines released by immune and nonimmune cells (including tumor cells and their microenvironment). irAEs can affect any organ system, and the implementation of early diagnosis and early intervention is critical to patient safety and is the key to the management of irAEs. Patients should be educated to report an irAE to their oncologist as soon as possible, even if the intensity of their symptoms is not serious. The typical treatment for irAEs is to suspend or continue ICI therapy, hospitalize if necessary, rule out the cause of infection, use steroids orally or intravenously, gradually reducing the dose over a period of several weeks. If hormone therapy is not effective, consideration should be given to using mycophenolate or infliximab (if there is no liver damage), and an affected

organ specialist should be consulted if necessary. The patients included in the above statistics had no evidence of pre-existing autoimmune diseases.

It becomes very challenging when oncologists must make decisions among many therapies with similar efficacy and/or specific toxicity characteristics. The advantage of meta-analysis in this study is that it may reduce publication bias and identify obvious results with higher efficiency. Due to the combination of smaller and larger studies, the effective sample size will be greatly increased. The results of this meta-analysis can help oncologists choose the type of ICI when deciding on an ICI plan and when planning to use ICIs for future research.

ICIs are effective against a variety of cancers. Compared with CTLA-4, PD-1 and PD-L1 have a lower incidence of iRAEs and still have clinical therapeutic effects. The limitations are as follows: single-agent different dose in immunotherapy treatment may have an impact on the outcome; most of the literature in this study is overseas; ICI-related domestic research does not show obvious advantages; the quality of the included research is lower; and there are few relevant studies. In the future, multicenter, large sample, and high quality research will be needed to further support and verify the findings of this study.

#### References

1 Brahmer JR, Lacchetti C, Schneider BJ *et al*. Management of immune-related adverse events in patients treated with

immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2018; **36**: 1714–68. https://doi.org/10.1200/JOP.18.00005.

- 2 Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO J* 1992; **11** (11): 3887–95.
- 3 NaoyaY, Tatsuya T, Manabu F, *et al.* Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). *Cancer Chemother Pharmacol* 2017; **79**: 651–660. https://doi:10.1007/s00280-016-3237-x.
- 4 DingW, LaPlant BR, Call TG Ding W et al.
  Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. *Blood* 2017; **129** 26: 3419–3427. https://doi:10.1182/blood-2017-02-765685.
- 5 Robert C, Schachter J, Long GV *et al.* Pembrolizumab versus Ipilimumab in advanced melanoma. *N Engl J Med* 2015; **372** (26): 2521–32. https://doi.org/10.1056/ NEJMoa1503093.
- 6 Garon EB, Rizvi NA, Hui R *et al.* Pembrolizumab for the treatment of non–small-cell lung cancer. *N Engl J Med* 2015; **372**: 2018–28. https://doi.org/10.1056/ NEJMoa1501824.
- 7 Patnaik A, Kang SP, Rasco D *et al.* Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. *Clin Cancer Res* 2015; **21** (19): 4286–93. https://doi.org/10.1158/ 1078-0432.CCR-14-2607.
- 8 Le DT, Uram JN, Wang H *et al.* PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015; **372** (26): 2509–20. https://doi.org/10.1056/NEJMoa1500596.
- 9 Ribas A, Puzanov I, Dummer R *et al.* Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. *Lancet Oncol* 2015; 16 (8): 908–18. https://doi.org/10.1016/S1470-2045(15) 00083-2.
- 10 Herbst RS, Baas P, Kim D-W et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. *Lancet* 2016; **387**: 1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7.
- 11 Shimizu T, Seto T, Fumihiko Hirai F *et al.* Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. *Invest New Drugs* 2016; **34**: 347–54. https://doi.org/10.1007/ s10637-016-0347-6.
- 12 Nghiem PT, Bhatia S, Lipson EJ et al. PD-1 blockade with Pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 2016; 374 (26): 2542–52. https://doi.org/10.1056/ NEJMoa1603702.
- 13 Muro K, Chung HC, Shankaran V *et al.* Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial.

- Seiwert TY, Burtness B, Mehra R *et al.* Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. *Lancet Oncol* 2016; **17** (7): 956–65. https://doi.org/10. 1016/S1470-2045(16)30066-3.
- 15 Goldberg SB, Gettinger SN, Mahajan A *et al.* A phase II trial of pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases. *Lancet Oncol* 2016; **17** (7): 976–83. https://doi.org/10.1016/ S1470-2045(16)30053-5.
- Reck M, Rodríguez-Abreu D, Robinson AG *et al.*Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. *N Engl J Med* 2016; **375** (19): 1823–33. https://doi.org/10.1056/NEJMoa1606774.
- 17 Ott PA, Piha-Paul SA, Munster P *et al.* Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. *Ann Oncol* 2017; 28: 1036–41. https://doi.org/ 10.1093/annonc/mdx029.
- 18 Plimack ER, Bellmunt J, Gupta S *et al.* Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): A non-randomised, openlabel, phase 1b study. *Lancet Oncol* 2017; **18** (2): 212–20. https://doi.org/10.1016/S1470-2045(17)30007-4.
- 19 Hui R, Garon EB, Goldman JW *et al.* Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: A phase 1 trial. *Ann Oncol* 2017; 28: 874–81. https://doi.org/10.1093/annonc/mdx008.
- 20 Chen R, Zinzani PL, Fanale MA *et al.* Phase II study of the efficacy and safety of Pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. *J Clin Oncol* 2017; **35**: 2125–32. https://doi.org/10.1200/JCO.2016. 72.1316.
- 21 Le DT, Durham JN, Smith KN *et al.* Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017; **357** (6349): 409–13. https://doi.org/ 10.1126/science.aan6733.
- 22 Schachter J. ibas A, Long GV et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, openlabel phase 3 study (KEYNOTE-006). *Lancet* 2017; **390** (10105): 1853–62. https://doi.org/10.1016/S0140-6736(17) 31601-X.
- 23 Balar AV, Castellano D, O'Donnell P-H *et al.* First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. *Lancet Oncol* 2017; **18** (11): 1483–92. https://doi.org/10. 1016/S1470-2045(17)30616-2.
- 24 Adra N, Einhorn LH, Althouse SK *et al.* Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: A Hoosier cancer research network study

GU14-206. Ann Oncol 2018; **29**: 209–14. https://doi.org/10. 1093/annonc/mdx680.

- 25 Giaccone G, Kim C, Thompson J *et al.* Pembrolizumab in patients with thymic carcinoma: A single-arm, singlecentre, phase 2 study. *Lancet Oncol* 2018; **19** (3): 347–55. https://doi.org/10.1016/S1470-2045(18)30062-7.
- 26 Cohen RB, Delord J-P, Toshihiko Doi T *et al.* Pembrolizumab for the treatment of advanced salivary gland carcinoma findings of the phase 1b KEYNOTE-028 study. *Am J Clin Oncol* 2018; **41**: 1083–8. https://doi.org/ 10.1097/COC.00000000000429.
- 27 Fuchs CS, Doi T, Jang RW *et al.* Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and Gastroesophageal junction cancer phase 2 clinical KEYNOTE-059 trial. *JAMA Oncol* 2018; 4 (5): e180013. https://doi.org/10.1001/jamaoncol. 2018.0013.
- 28 Rugo HS, Delord J-P, Im S-A *et al.* Safety and antitumor activity of Pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. *Clin Cancer Res* 2018; 24 (12): 2804–11. https://doi.org/10.1158/1078-0432.CCR-17-3452.
- 29 Eggermont AMM, Blank CU, Mandala M et al. Adjuvant Pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018; 378 (19): 1789–801. https:// doi.org/10.1056/NEJMoa1802357.
- 30 Zhu AX, Finn RS, Edeline J *et al.* Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A nonrandomised, open-label phase 2 trial. *Lancet Oncol* 2018; **19** (7): 940–52. https://doi.org/10.1016/S1470-2045(18) 30351-6.
- 31 Shitara K, Özgüroğlu M, Bang Y-J et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet 2018; **392** (10142): 123–33. https://doi.org/10.1016/S0140-6736(18)31257-1.
- 32 Hansen AR, Massard C, Ott PA *et al*. Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study. *Ann Oncol* 2018; 29: 1807–13. https://doi.org/10.1093/annonc/mdy232.
- 33 Cohen EEW, Soulières D, Le Tourneau C et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. *Lancet* 2019; 393 (10167): 156–67. https://doi.org/10.1016/S0140-6736(18) 31999-8.
- 34 Varga A, Piha-Paul S, Ott PA *et al.* Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. *Gynecol Oncol* 2019; **152** (2): 243–50. https://doi.org/10. 1016/j.ygyno.2018.11.017.

- 35 Shah MA, Kojima T, Hochhauser D *et al.* Efficacy and safety of Pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus the phase 2 KEYNOTE-180 study. *JAMA Oncol* 2019; **5** (4): 546–50. https://doi. org/10.1001/jamaoncol.2018.5441.
- 36 Levy BP, Giaccone G, Besse B et al. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Eur J Cancer 2019; 108: 120–8. https://doi.org/10.1016/j.ejca.2018.11.028.
- 37 Mok TSK, Wu Y-L, Kudaba I *et al.* Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. *Lancet* 2019; **393** (10183): 1819–30. https:// doi.org/10.1016/S0140-6736(18)32409-7.
- 38 Bang Y-J, Kang Y-K, Catenaccl DV *et al.* Pembrolizumab alone or in combination with chemotheration as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: Results from the phase II nonrandomized KEYNOTE-059 study. *Gastric Cancer* 2019; **22** (4): 828–37. https://doi.org/10.1007/ s10120-018-00909-5.
- 39 Si L, Zhang X, Shu Y *et al.* A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151). *Transl Oncol* 2019; **12**: 828–35. https://doi.org/10.1016/j. tranon.2019.02.007.
- 40 Chung HC, Ros W, Delord J-P *et al.* Efficacy and safety of Pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. *J Clin Oncol* 2019; **37** (17): 1470–8. https://doi.org/10.1200/ JCO.18.01265.
- 41 Fradet Y, Bellmunt J, Vaughn DJ et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: Results of > 2 years of follow-up. Ann Oncol 2019; 30: 970–976. doi: 10.1093/annonc/mdz127. pii: mdz127.
- 42 Nanda R, Chow LQ, Dees EC *et al.* Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. *J Clin Oncol* 2016; 34 (21): 2460–7. https://doi.org/10.1200/JCO.2015.64.8931.
- 43 Alley EW, Lopez J, Santoro A *et al.* Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial. *Lancet Oncol* 2017; **18** (5): 623–30. https://doi.org/10.1016/S1470-2045(17)30169-9.
- 44 Bauml J, Seiwert TY, Pfister DG *et al.* Pembrolizumab for platinum- and Cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study. *J Clin Oncol* 2017; **35** (14): 1542–9. https://doi.org/10.1200/JCO.2016. 70.1524.

- 45 Hsu C, Lee SH, Ejadi S *et al.* Safety and antitumor activity of Pembrolizumab in patients with programmed deathligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study. *J Clin Oncol* 2017; **35** (36): 4050–6. https://doi.org/10.1200/JCO.2017.73.3675.
- 46 Frenel JS, Le Tourneau C, O'Neil B *et al.* Safety and efficacy of Pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: Results from the phase Ib KEYNOTE-028 trial. *J Clin Oncol* 2017; **35** (36): 4035–41. https://doi.org/10.1200/JCO.2017.74.5471.
- 47 Doi T, Piha-Paul SA, Jalal SI *et al.* Safety and antitumor activity of the anti-programmed death-1 antibody Pembrolizumab in patients with advanced esophageal carcinoma. *J Clin Oncol* 2018; **36** (1): 61–7. https://doi.org/ 10.1200/JCO.2017.74.9846.
- 48 Adams S, Loi S, Toppmeyer D *et al.* Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. *Ann Oncol* 2019; **30** (3): 405–11. https://doi.org/10.1093/annonc/mdy518.
- 49 Topalian SL, Sznol M, McDermott DF *et al.* Survival, durable tumor remission, and Long-term safety in patients with advanced melanoma receiving Nivolumab. *J Clin Oncol* 2014; **32** (10): 1020–30. https://doi.org/10.1200/JCO. 2013.53.0105.
- 50 Hellmann MD, Callahan MK, Awad MM et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with Ipilimumab in small-cell lung cancer. Cancer Cell 2018; 33: 853–61. https://doi.org/10. 1016/j.ccell.2018.04.001.
- 51 Kato K, Satoh T, Muro K *et al.* A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). *Gastric Cancer* 2019; **22** (2): 344–54. https://doi.org/10.1007/s10120-018-0899-6.
- 52 Scherpereel A, Mazieres J, Greillier L *et al.* Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial. *Lancet Oncol* 2019; **20** (2): 239–53. https:// doi.org/10.1016/S1470-2045(18)30765-4.
- 53 Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. *Nat Med* 2019; **25** (3): 470–6. https://doi.org/10.1038/s41591-018-0339-5.
- 54 Yamamoto N, Nokihara H, Yamada Y *et al*. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. *Invest New Drugs* 2017; **35** (2): 207–16. https://doi.org/10.1007/s10637-016-0411-2.
- 55 Younes A, Santoro A, Shipp M *et al.* Nivolumab for classical Hodgkin lymphoma after autologous stem-cell

transplantation and brentuximab vedotin failure: A prospective phase 2 multi-cohort study. *Lancet Oncol* 2016; **17** (9): 1283–94. https://doi.org/10.1016/S1470-2045(16) 30167-X.

- 56 Maruyama D, Hatake K, Kinoshita T *et al.* Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. *Cancer Sci* 2017; **108** (5): 1007–12. https://doi.org/10.1111/cas. 13230.
- 57 Overman MJ, McDermott R, Leach JL *et al.* Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability-high colorectal cancer (CheckMate 142): Results of an open-label, multicentre, phase 2 study. *Lancet Oncol* 2017; **18** (9): 1182–91. https:// doi.org/10.1016/S1470-2045(17)30422-9.
- 58 Long GV, Atkinson V, Lo S *et al.* Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study. *Lancet Oncol* 2018; **19** (5): 672–81. https://doi.org/10.1016/ S1470-2045(18)30139-6.
- 59 Yamazaki N, Kiyohara Y, Uhara H *et al.* Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study. *Cancer Sci* 2017; **108**: 1223–30. https://doi.org/10.1111/cas.13241.
- 60 Nishio M, Hida T, Atagi S *et al.* Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. *ESMO Open* 2017; **1** (4): e000108. https://doi.org/10.1136/ esmoopen-2016-000108.
- 61 Hida T, Nishio M, Nogami N *et al.* Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. *Cancer Sci* 2017; 108 (5): 1000–6. https://doi.org/10.1111/cas.13225.
- Kudo T, Hamamoto Y, Kato K *et al.* Nivolumab treatment for oesophageal squamous-cell carcinoma: An open-label, multicentre, phase 2 trial. *Lancet Oncol* 2017; 18 (5): 631–9. https://doi.org/10.1016/S1470-2045(17) 30181-X.
- 63 Hamanishi J, Mandai M, Ikeda T *et al.* Safety and antitumor activity of anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian cancer. *J Clin Oncol* 2015; **33** (34): 4015–22. https://doi.org/10.1200/JCO. 2015.62.3397.
- 64 Rizvi NA, Mazières J, Planchard D *et al*. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous nonsmall-cell lung c ancer (CheckMate 063): A phase 2, singlearm trial. *Lancet Oncol* 2015; **16**: 257–65. https://doi.org/10. 1016/S1470-2045(15)70054-9.
- 65 D'Angelo SP, Mahoney MR, Van Tine BA *et al.* Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, noncomparative, randomised, phase 2 trials. *Lancet Oncol* 2018; **19** (3): 416–26. https://doi.org/10.1016/S1470-2045 (18)30006-8.

- 66 Ansell SM, Lesokhin AM, Ivan Borrello I *et al.* PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med* 2015; **372** (4): 311–9. https://doi.org/10.1056/NEJMoa1411087.
- 67 Orghaei H, Paz-Ares L, Horn L *et al.* Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med* 2015; **373** (17): 1627–39. https://doi. org/10.1056/NEJMoa1507643.
- 68 Brahmer J, Reckamp KL, Baas P *et al*. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; **373** (2): 123–35. https://doi. org/10.1056/NEJMoa1504627.
- 69 Motzer RJ, Escudier B, McDermott DF *et al.* Nivolumab versus Everolimus in advanced renal-cell carcinoma. *N Engl J Med* 2015; **373** (19): 1803–13. https://doi.org/10. 1056/NEJMoa1510665.
- 70 Weber JS, D'Angelo SP, Minor D *et al.* Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. *Lancet Oncol* 2015; **16** (4): 375–84. https://doi.org/10.1016/S1470-2045(15)70076-8.
- 71 Carbone DP, Reck M, Paz-Ares L *et al.* First-line Nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J Med 2017; **376** (25): 2415–26. https://doi. org/10.1056/NEJMoa1613493.
- 72 Larkin J, Chiarion-Sileni V, Gonzalez R *et al.* Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. *N Engl J Med* 2015; **373** (1): 23–34. https://doi. org/10.1056/NEJMoa1504030.
- 73 Kang Y-K, Boku N, Satoh T *et al*. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017; **390**: 2461–71. https://doi.org/10.1016/S0140-6736(17)31827-5.
- 74 Ferris RL, Blumenschein G, Fayette J et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375 (19): 1856–67. https://doi.org/10. 1056/NEJMoa1602252.
- 75 Zhao B, Zhao H, Zhao J. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events. *J Immunother Cancer* 2018; 6 (1): 101. https://doi. org/10.1186/s40425-018-0421-z.
- 76 Herbst RS, Soria JC, Kowanetz M *et al.* Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature* 2014; 515 (7528): 563–7. https://doi.org/10.1038/nature14011.
- 77 McDermott DF, Sosman JA, Sznol M *et al*. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase Ia study. *J Clin Oncol*

2016; **34** (8): 833-42. https://doi.org/10.1200/JCO.2015. 63.7421.

- 78 Balar AV, Galsky MD, Rosenberg JE *et al.* Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. *Lancet* 2017; **389**: 67–76. https://doi.org/10.1016/S0140-6736(16)32455-2.
- 79 Rittmeyer A, Barlesi F, Waterkamp D *et al.* Atezolizumab versus docetaxel in patients with previously treated nonsmall-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. *Lancet* 2017; **389** (10066): 255–65. https://doi.org/10.1016/S0140-6736(16) 32517-X.
- 80 Peters S, Gettinger S, Johnson ML *et al.* Phase II trial of Atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). *J Clin Oncol* 2017; **35** (24): 2781–9. https://doi.org/10.1200/JCO.2016. 71.9476.
- 81 Powles T, Durán I, van der Heijden MS *et al.* Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2018; **391** (10122): 748–57. https://doi.org/10.1016/S0140-6736(17)33297-X.
- 82 Petrylak DP, Powles T, Bellmunt J et al. Atezolizumab (MPDL3280A) Monotherapy for patients with metastatic urothelial cancer: Long-term outcomes from a phase 1 study. JAMA Oncol 2018; 4 (4): 537–44. https://doi.org/10. 1001/jamaoncol.2017.5440.
- 83 Spigel DR, Chaft JE, Gettinger S *et al.* Efficacy, safety, and biomarker analysis of a phase II open-label study of Atezolizumab in PD-L1-selected patients with NSCLC. *J Thorac Oncol* 2018; **13** (11): 1733–42. https://doi.org/10. 1016/j.jtho.2018.05.004.
- 84 Lukas RV, Rodon J, Becker K *et al.* Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. *J Neurooncol* 2018; **140** (2): 317–28. https:// doi.org/10.1007/s11060-018-2955-9.
- 85 Horn L, Gettinger SN, Gordon MS *et al.* Safety and clinical activity of atezolizumab monotherapy in metastatic nonsmall-cell lung cancer: Final results from a phase I study. *Eur J Cancer* 2018; **101**: 201–9. https://doi.org/10.1016/j. ejca.2018.06.031.
- 86 Colevas AD, Bahleda R, Braiteh F *et al.* Safety and clinical activity of atezolizumab in head and neck cancer: Results from a phase I trial. *Ann Oncol* 2018; **29** (11): 2247–53. https://doi.org/10.1093/annonc/mdy411.
- 87 Fehrenbacher L, Spira A, Ballinger M *et al.* Atezolizumab versus docetaxel for patients with previously treated nonsmall-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. *Lancet* 2016; **387** (10030): 1837–46. https://doi.org/10.1016/S0140-6736(16)00587-0.

- 88 Eng C, Kim TW, Bendell J *et al.* Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): A multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol* 2019; **20** (6): 849–61. https://doi.org/10. 1016/S1470-2045(19)30027-0.
- 89 Kaufman HL, Russell J, Hamid O *et al*. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. *Lancet Oncol* 2016; **17** (10): 1374–85. https:// doi.org/10.1016/S1470-2045(16)30364-3.
- 90 Gulley JL, Rajan A, Spigel DR *et al.* Avelumab for patients with previously treated metastatic or recurrent non-smallcell lung cancer (JAVELIN solid tumor): Dose-expansion cohort of a multicentre, open-label, phase 1b trial. *Lancet Oncol* 2017; **18** (5): 599–610. https://doi.org/10.1016/S1470-2045(17)30240-1.
- 91 Heery CR, O'Sullivan-Coyne G, Madan RA *et al.* Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN solid tumor): A phase 1a, multicohort, dose-escalation trial. *Lancet Oncol* 2017; **18** (5): 587–98. https://doi.org/10.1016/S1470-2045(17)30239-5.
- 92 Apolo AB, Infante JR, Balmanoukian A et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. J Clin Oncol 2017; 35 (19): 2117–24. https://doi.org/10.1200/JCO.2016.71.6795.
- 93 Dirix LY, Takacs I, Jerusalem G et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat 2018; 167 (3): 671–86. https://doi.org/10.1007/s10549-017-4537-5.
- 94 Patel MR, Ellerton J, Infante JR *et al.* Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): Pooled results from two expansion cohorts of an open-label, phase 1 trial. *Lancet Oncol* 2018; 19 (1): 51–64. https://doi.org/10.1016/S1470-2045(17) 30900-2.
- 95 Kelly K, Infante JR, Taylor MH *et al.* Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. *Cancer* 2018; **124** (9): 2010–7. https://doi.org/10.1002/cncr.31293.
- 96 Bang YJ, Ruiz EY, Van Cutsem E *et al.* Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN gastric 300. *Ann Oncol* 2018; 29 (10): 2052–60. https://doi.org/10.1093/annonc/mdy264.
- 97 Barlesi F, Vansteenkiste J, Spigel D et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN lung 200): An open-label, randomised, phase 3 study. Lancet Oncol 2018; 19 (11): 1468–79. https://doi.org/10.1016/S1470-2045(18)30673-9.

- 98 Le Tourneau C, Hoimes C, Zarwan C et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: Phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer 2018; 6 (1): 111. https://doi.org/ 10.1186/s40425-018-0424-9.
- 99 Hassan R, Thomas A, Nemunaitis JJ *et al.* Efficacy and safety of Avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN solid tumor trial. *JAMA Oncol* 2019; 5 (3): 351– 7. https://doi.org/10.1001/jamaoncol.2018.5428.
- 100 Keilholz U, Mehnert JM, Bauer S *et al.* Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN solid tumor trial. *J Immunother Cancer* 2019; 7 (1): 12. https://doi.org/10. 1186/s40425-018-0459-y.
- 101 Disis ML, Taylor MH, Kelly K *et al.* Efficacy and safety of Avelumab for patients with recurrent or refractory ovarian cancer: Phase 1b results from the JAVELIN solid tumor trial. *JAMA Oncol* 2019; **5** (3): 393–401. https://doi.org/10. 1001/jamaoncol.2018.6258.
- 102 Chung HC, Arkenau HT, Lee J *et al*. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results from the JAVELIN solid tumor trial. *J Immunother Cancer* 2019; 7 (1): 30. https://doi.org/10.1186/s40425-019-0508-1.
- 103 Massard C, Gordon MS, Sharma S *et al.* Safety and efficacy of Durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. *J Clin Oncol* 2016; **34** (26): 3119–25. https://doi.org/10.1200/JCO.2016.67.9761.
- 104 Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377 (20): 1919–29. https://doi.org/10. 1056/NEJMoa1709937.
- 105 Garassino MC, Cho BC, Kim JH *et al.* Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): An open-label, single-arm, phase 2 study. *Lancet Oncol* 2018; **19** (4): 521–36. https:// doi.org/10.1016/S1470-2045(18)30144-X.
- 106 Powles T, O'Donnell PHC, Massard C et al. Efficacy and safety of Durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1/2 open-label study. JAMA Oncol 2017; 3: e172411. https:// doi.org/10.1001/jamaoncol.2017.2411.
- 107 Yang H, Shen K, Zhu C *et al.* Safety and Efficacy of Durvalumab (MEDI4736) in Various Solid Tumors. *Drug des Devel Ther* 2018; 12: 2085–96. https://doi.org/10.2147/ DDDT.S162214.
- 108 Rotman J, Mom CH, Jordanova ES, de Gruijl TD, Kenter GG. 'DURVIT': A phase-I trial of single low-dose durvalumab (Medi4736) intratumourally injected in cervical cancer: Safety, toxicity and effect on the primary tumour- and lymph node microenvironment. BMC Cancer 2018;18(1):888. doi:10.1186/s12885-018-4764-0

- 109 Siu LL, Even C, Mesía R *et al.* Safety and efficacy of Durvalumab with or without Tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: The phase 2 CONDOR randomized clinical trial. *JAMA Oncol* 2019; 5 (2): 195–203. https://doi.org/10.1001/ jamaoncol.2018.4628.
- 110 Zandberg DP, Algazi AP, Jimeno A *et al.* Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. *Eur J Cancer* 2019; **107**: 142–52. https://doi.org/10.1016/j.ejca. 2018.11.015.
- 111 Segal NH, Ou SI, Balmanoukian A *et al.* Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: Results from a phase I/II expansion cohort. *Eur J Cancer* 2019; **109**: 154–61. https://doi.org/10.1016/j. ejca.2018.12.029.
- 112 Small TJ, Tchekmedyian NS, Rini BI *et al.* A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. *Clin Cancer Res* 2007; **13** (6): 1810–5. https://doi.org/10.1158/1078-0432. CCR-06-2318.
- 113 Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castrationresistant prostate cancer: Results from an open-label, multicenter phase I/II study. Ann Oncol 2013; 24: 1813–21. https://doi.org/10.1093/annonc/mdt107.
- 114 Weber JS, O'Day S, Urba W et al. Phase I/II study of Ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26: 5950–6. https://doi.org/10.1200/JCO.2008. 16.1927.
- 115 Yamazaki N, Kiyohara Y, Uhara H et al. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. *Cancer Chemother Pharmacol* 2015; 76: 997–1004. https://doi.org/10.1007/s00280-015-2873-x.
- 116 Eggermont AMM, Chiario-Sileni V, Grob J-J et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med 2016; 375 (19): 1845–55. https://doi.org/10.1056/NEJMoa1611299.
- 117 Ascierto PA, Del Vecchio M, Robert C *et al.* Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol* 2017;
  18 (5): 611–22. https://doi.org/10.1016/S1470-2045(17) 30231-0.
- 118 Beer TM, Kwon ED, Drake CG *et al.* Randomized, doubleblind, phase III trial of Ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naïve castration-resistant prostate cancer. *J Clin Oncol* 2017; **35** (1): 40–7. https://doi.org/10. 1200/JCO.2016.69.1584.
- 119 Chesney J, Puzanov I, Collichio F et al. Randomized, openlabel phase II study evaluating the efficacy and safety of Talimogene laherparepvec in combination with Ipilimumab

versus Ipilimumab alone in patients with advanced, unresectable melanoma. *J Clin Oncol* 2018; **36** (17): 1658– 67. https://doi.org/10.1200/JCO.2017.73.7379.

- 120 Weber J, Mandala M, Del Vecchio M et al. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017;377:1824–35. doiI: 10.1056/NEJMoa1709030
- 121 Bang YJ, Cho JY, Kim YH *et al.* Efficacy of sequential Ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer. *Clin Cancer Res* 2017; 23 (19): 5671–8. https://doi.org/10.1158/1078-0432.CCR-17-0025.
- 122 Zimmer L, Eigentler TK, Kiecker F et al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J Transl Med 2015; 13:351. doiI: 10.1186/s12967-015-0716-5
- 123 Weber J, Hamid O, Amin A *et al.* Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. *Cancer Immun* 2013; 13: 7.
- 124 Geoerger B, Bergeron C, Gore L et al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer 2017; 86: 358–63. https://doi.org/10.1016/j.ejca.2017.09.032.
- 125 Hersh EM, O'Day SJ, Powderly J et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. *Invest New Drugs* 2011; 29: 489–98. https://doi. org/10.1007/s10637-009-9376-8.
- Hamid O, Schmidt H, Nissan A *et al.* A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. *Journal of Translational Medicine* 2011; 9: 204. https://doi.org/10. 1186/1479-5876-9-204.
- 127 Postow MA, Chesney J, Pavlick AC et al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J Med 2015; 372 (21): 2006–17. https://doi.org/10. 1056/NEJMoa1414428.
- 128 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and Ipilimumab or monotherapy in previously untreated melanoma. N Engl J Med 2015; 373 (1): 23–34. https://doi.org/10.1056/NEJMoa1504030.
- Hodi FS, Lee S, McDermott DF *et al.* Sargramostim plus Ipilimumab vs Ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial. *JAMA* 2014; **312** (17): 1744–53. https://doi.org/10.1001/jama.2014. 13943.
- 130 Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (8): 711–23. https://doi.org/10.1056/ NEJMoa1003466.

- 131 Weber J, Thompson JA, Hamid O et al. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma. *Clin Cancer Res* 2009; **15** (17): 5591–8. https://doi.org/10.1158/ 1078-0432.CCR-09-1024.
- 132 ODay SJ, Maio M, Chiarion-Sileni V, SJ et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma:a multicenter single-arm phase II study. Annals of Oncology 2010; 21: 1712–1717. https://doi.org/10.1093/annonc/mdq013.
- 133 Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *Lancet Oncol* 2010; 11: 155–64. https://doi:10.1016/S1470-2045(09)70334-1.
- 134 Camacho LH, Antonia S, Sosman J *et al.* Phase I/II trial of Tremelimumab in patients with metastatic melanoma. *J Clin Oncol* 2009; 27: 1075–81. https://doi.org/10.1200/JCO. 2008.19.2435.
- 135 Kirkwood JM, Lorigan P, Hersey P *et al.* Phase II trial of Tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. *Clin Cancer Res* 2010; 16 (3): 1042–8. https://doi.org/10.1158/1078-0432.CCR-09-2033.
- 136 Chung KY, Gore I, Fong L *et al.* Phase II study of the anti-cytotoxic T-lymphocyte–associated antigen 4 monoclonal antibody, Tremelimumab, in patients with refractory metastatic colorectal cancer. *J Clin Oncol* 2010; 28: 3485–90. https://doi.org/10.1200/JCO.2010. 28.3994.
- 137 Ribas A, Kefford R, Marshall MA *et al.* Phase III randomized clinical trial comparing Tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. *J Clin Oncol* 2013; **31**: 616–22. https://doi.org/ 10.1200/JCO.2012.44.6112.
- 138 Calabrò L, Morra A, Fonsatti E *et al.* Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial. *Lancet Oncol* 2013; **14** (11): 1104–11. https://doi.org/10. 1016/S1470-2045(13)70381-4.
- 139 Joshua AM, Monzon JG, Mihalcioiu C et al. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. *Melanoma Res* 2015; 25 (4): 3427. https://doi. org/10.1097/CMR.
- 140 Maio M, Scherpereel A, Calabrò L *et al.* Tremelimumab as second-line or third-line treatment in relapsed malignant

mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. *Lancet Oncol* 2017; **18** (9): 1261–73. https:// doi.org/10.1016/S1470-2045(17)30446-1.

- 141 Xu R, Wang F, Li Q et al. Recombinant humanised anti-PD-1 monoclonal antibody (JS001) treatment for patients with refractory or metastatic nasopharyngeal carcinoma: preliminary results of an open-label, phase 1b/2, clinical study. *Lancet Oncol.* 2017;18 S1. https://doi.org/10.1016/ S1470-2045(17)30757-X.
- 142 Tang B, Yan X, Sheng X *et al.* Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. *J Hematol Oncol* 2019; **12**: 7. https://doi.org/10.1186/s13045-018-0693-2.
- 143 Zhang P, Lu M, Li J et al. Efficacy and safety of PD-1 blockade with JS001 in patients with advanced neuroendocrine neoplasms: A non-randomized, open-label, phase Ib trial. Ann Oncol 2018; 29: viii467–viii478. https:// doi.org/10.1093/annonc/mdy293.002.
- 144 Huang J, Mo H, Zhang W et al. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. Cancer 2019; 125 (5): 742–9. https://doi.org/10.1002/cncr.31855.
- 145 Nie J, Wang C, Liu Y *et al.* Addition of low-dose Decitabine to anti-PD-1 antibody Camrelizumab in relapsed/refractory classical Hodgkin lymphoma. *J Clin Oncol* 2019; **37** (17): 1479–89. https://doi.org/10.1200/JCO. 18.02151.
- 146 Fang W, Yang Y, Ma Y *et al.* Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: Results from two single-arm, phase 1 trials. *Lancet Oncol* 2018; **19** (10): 1338–50. https:// doi.org/10.1016/S1470-2045(18)30495-9.
- 147 Mo H, Huang J, Xu J et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: A dose-escalation, phase 1 study. Br J Cancer 2018; 119 (5): 538–45. https:// doi.org/10.1038/s41416-018-0100-3.
- 148 Shi Y, Su H, Song Y *et al.* Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): A multicentre, single-arm, phase 2 trial. *Lancet Haematol* 2019; **6** (1): e12–9. https://doi.org/ 10.1016/S2352-3026(18)30192-3.
- 149 Migden MR, Rischin D, Schmults CD et al. PD-1 blockade with Cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018; 379 (4): 341–51. https://doi. org/10.1056/NEJMoa1805131.